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CHAPTER I 
 
INTRODUCTION 
 
Biomarker Discovery 
 The NIH defined biomarkers as characteristics that are objectively 
measured and evaluated as indicators of normal biological processes, 
pathogenic processes, or pharmacologic responses to therapeutic interventions.1  
In a disease such as cancer the identification of a molecule or molecular 
signature that is accurately indicative of these processes will be of extraordinary 
benefit to clinicians and patients.2   
The main hypothesis driving the search for cancer biomarkers is the 
concept that organs secrete a specific set of proteins representing a molecular 
signature indicative of its physiological state.3  In cancer patients this set of 
secreted proteins should alter to reflect the genetic mutations and other 
processes that contribute to the cancer phenotype.3  Detection and 
characterization of these molecular fingerprints has begun to provide a unique 
view of the proteomic changes associated with disease status.  The potential use 
of biomarkers for the early detection of cancer has compelled significant research 
in this field.2, 4   
 Another advantage of biomarkers is the potential to aid clinicians in 
selecting patients to undergo certain treatments.  This research is conducted 
based on previous evaluations of treatment efficacy and safety from patients 
 2 
 
exhibiting a specific biomarker.  These markers may also be used to monitor 
response to treatment and disease progression.5  
Various biological specimens, including blood, urine, and saliva, have 
been analyzed for the discovery of potential biomarker candidates.  One of the 
major goals in this field of research is the development of a blood-based assay 
for the detection of biomarkers, due to the relatively easy and non-invasive 
manner in which blood can be collected.  Blood, however, poses many significant 
challenges to researchers during the discovery phase.  The range of protein 
concentrations in blood is extensive, ranging from albumin at ~40 mg/mL, to 
cytokines at ~5 pg/mL.2  Moreover, a set of 22 proteins account for 99% of the 
total protein content in blood.6, 7  This compositional complexity makes the 
detection of low abundance proteins extremely difficult when using common 
separation techniques such as 2-DIGE and HPLC. 
 Immunodepletion technologies were developed to reduce the presence of 
the high abundance proteins in complex samples.6   Although these depletion 
strategies have proven effective, they are not without limitations.  For example, 
immunodepletion of albumin from serum with a removal efficiency of 99% leaves 
a remaining concentration of approximately 50 μg/mL, which is still significantly 
higher than most proteins of interest.  Furthermore, non-specific removal of 
proteins other than the target and possible binding of target proteins to other 
proteins, like albumin, will inevitably result in concomitant depletion of potentially 
useful markers.  The extremely dynamic nature of the plasma proteome adds yet 
another variable to consider when profiling these samples.  Factors such as 
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genetic polymorphisms, gender, age, ethnicity, and lifestyle can significantly alter 
the protein species detected in blood.  Variations arising from inconsistent 
sample collection and storage procedures (e.g. processing time, storage 
temperature) may further exacerbate these fluctuations in the proteome.     
 These shortcomings have encouraged research looking at alternative 
sources, such as tumor biopsy tissues, for biomarker discovery.  In theory, the 
concentrations of potential biomarkers are expected to be highest in the tumor 
and the microenvironment of the surrounding tissue.  Upon entry into circulation 
via the lymphatic system, these markers will be significantly diluted into the 
complex matrix of the blood.  Therefore, the direct analysis of the tumor and 
surrounding tissue should be the most logical source to carry out the discovery 
phase of biomarkers.  The markers identified in this way could then be detected 
in blood using highly specific technologies such as multiple reaction monitoring 
(MRM) or immunoassays.    
 
Imaging Mass Spectrometry 
 Molecular imaging has played a pivotal role in our understanding of the 
spatial complexity of biological systems at the tissue and cellular level.8  Several 
different approaches are commonly used to examine the spatial distribution of 
molecules in biological samples including fluorescence9, immunohistochemistry 
(IHC)10, positron emission topography11, and magnetic resonance imaging 
(MRI)12.  Although these technologies represent powerful and well-established 
imaging tools, there are several limitations present with these approaches.  Most 
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notably, these methodologies generally employ a targeted approach that requires 
an a priori knowledge of the molecule(s) of interest, thus limiting their 
effectiveness as true discovery tools.  Furthermore, these techniques are only 
capable of analyzing a small number of components simultaneously and 
therefore provide a limited, albeit valuable, view of the biological system.   
Over the past several years, imaging mass spectrometry (IMS) has 
emerged as a powerful tool for studying the spatial arrangement of proteins, 
peptides, lipids, and small molecules in tissues.13-15  The multichannel detection 
capability of mass spectrometry enables the position sensitive analysis of 
hundreds of different molecules in a single experiment.13, 14  This is achieved by 
acquiring mass spectra across a sample at precisely defined geometrical 
coordinates. Post acquisition processing compiles the mass spectra into a format 
in which any of the detected species can be viewed as an ion density map, 
where the relative abundance of the selected ion across the sample is displayed 
on a color intensity scale at each coordinate location (pixel) (Figure 1). Unlike 
other molecular visualization techniques, IMS does not require a target specific 
reagent and it is therefore a valuable discovery tool. 
 
History 
 IMS has been conducted on a wide range of analytes using a variety of 
different ionization and mass analyzer combinations.  As early as the 1960s, 
secondary ion mass spectrometry (SIMS) was used to examine the distribution of  
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light elements (Na+, K+, Ca2+) or exogenous, isotopically labeled elements.16  The 
desorption and ionization process in SIMS is a highly energetic process that 
results in extensive molecular fragmentation, thereby limiting the practical mass 
range to small molecule analysis.  During the 1990s, polyatomic primary ion 
beams and the liquid metal ion gun were developed to extend the effective mass 
range of SIMS by providing a softer ionization process, which allowed analysis of 
cholesterol, lipids, and other small molecules up to ~1,000 Da.17-19  Despite 
significant advances in the ion generation process in SIMS instruments, larger 
biological molecules such as peptides, proteins, and oligonucleotides cannot be 
effectively analyzed using this technique.  It should be noted, however, that for 
small molecule imaging experiments SIMS provides superior spatial resolution 
relative to alternative techniques and is capable of imaging sub-cellular 
components.20 
 With the introduction of matrix-assisted laser desorption/ionization 
(MALDI) in the mid 1980s 21, 22 intact high molecular weight analytes could be 
efficiently desorbed and ionized for detection in a mass spectrometer.  Along with 
electrospray ionization23 (ESI), these soft ionization techniques would become 
the basis for a revolution in bioanalytical mass spectrometry and advance the 
field into a new era.   
 In 1997, Caprioli et al.24 demonstrated that MALDI MS could be used to 
map the location and relative intensity of proteins and peptides in a tissue 
section.  In the years since this pioneering work, IMS has evolved into a highly 
versatile technique with a broad range of functionality and applications.14, 25, 26 
 7 
 
The Technology 
 A brief description of the general workflow for an imaging experiment will 
be described in the following text; more detailed information can be found in 
several previously published works. 27, 28  It should be noted that a complimentary 
technique termed direct tissue profiling, is carried out in exactly the same manner 
as an imaging experiment with the exception that the data is not necessarily 
acquired in an arrayed pattern for generating ion density maps.  Profiling 
experiments are carried out when the desired area of analysis is small, and mass 
spectra acquisition is only necessary at a limited number of positions.  
 
Tissue Collection 
 To begin, a fresh frozen or formalin-fixed paraffin-embedded (FFPE) 
tissue specimen (e.g. tumor biopsy) is cut into thin sections (~12 μm for frozen; 
~5 μm for FFPE) and mounted onto a conductive MALDI target, typically a gold 
coated plate or indium tin oxide (ITO) coated microscope slide.  Frozen tissues 
are sectioned in a cryostat and are thaw mounted onto the target.  The tissues 
and MALDI target are slowly equilibrated to room temperature and then dried in a 
vacuum desiccator. For protein and peptide IMS experiments, these adhered 
sections are typically washed using a series of graded ethanol solutions to 
remove salts, lipids, and other contaminants that may result in ion suppression.29  
Some IMS experiments, such as those specifically targeting lipids, do not employ 
these wash steps because they may remove the molecules of interest.30  
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FFPE tissues are sectioned at room temperature using a microtome. The 
sections are floated in a temperature controlled water bath (37° C) and then 
mounted onto the MALDI target.  The FFPE sections are then deparaffinized and 
antigen retrieved prior to MS analysis (these steps will be described in more 
detail in Chapter 3).  
 
Matrix Application 
 The most commonly used MALDI matrices include 3,5-dimethoxy-4-
hydroxy-cinnamic acid (sinnapinic acid, SA), 2,5-dihydroxybenzoic acid (DHB), 
and α-cyano-4-hydroxycinnamic acid (CHCA).  The matrix and solvent 
composition used will vary depending on the specific molecule and/or tissue 
being investigated.  For example, SA is the most suitable matrix to be used in 
protein imaging experiments (m/z > 2000); whereas, DHB and CHCA provide 
superior performance in the low molecular weight mass range of peptides, lipids, 
and small molecules (m/z 100-2000).  These findings have been mostly empirical 
and the fundamental mechanism behind the performance of the different 
matrices is not well understood, yet more information regarding this topic can be 
found in several recently published articles.31-34 
 Matrix application can be carried out using several different approaches.  
The two most commonly used approaches are spray coating, which applies a 
homogenous layer of matrix across the tissue, or spotting, which generates an 
array of discrete matrix spots across the sample.  The advantage of spray 
coating is that the matrix is applied as a homogenous coating across the sample 
 9 
 
allowing mass spectrometric acquisition to be carried out at high spatial 
resolutions limited only by the spot size of the laser.  Spray coated matrix 
applications, however, often result in poor signal quality due to insufficient 
analyte extraction from the tissue during the relatively short solvent drying time.  
Furthermore, replication of exact spray conditions (e.g. humidity) and volumes, 
especially when carried out manually, can be difficult to achieve resulting in poor 
reproducibility between samples. 
 Alternatively, microspotting can be used to apply discrete droplets of 
matrix into defined arrays across a sample.  Microspotting enables precise 
volumes to be reproducibly deposited at each position over several iterations.  
This is important when comparing the relative ion intensities across a sample, 
because inconsistencies in the matrix application will lead to artificial variation in 
signal intensities.   
  Two commercially available robotic spotters were used in this research.  
The Portrait 630 (Labcyte; Sunnyvale, CA), shown in Figure 2a,  uses acoustic 
droplet ejection technology to emit a sound wave at a precisely defined power 
and focus into a solution reservoir, ejecting a ~170 pL droplet onto the adjacent 
sample surface.  This instrument is nozzle-free and droplets can be ejected at a 
frequency of up to 200 Hz.  The Portrait offers two separate working modes: 
start/stop mode, which can be used to deposit multiple drops at each position, 
and flyby mode, which moves the sample stage in a continuous motion while 
depositing a single drop at each position.  When printing in flyby mode, a single  
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droplet ejection pattern covering approximately 1 cm2 can be completed in less 
than 2 min.   
 The other instrument is a piezoelectric based chemical inkjet printer (ChIP; 
Shimadzu; Kyoto, Japan), shown in Figure 2b, that ejects ~80 pL droplets from a 
print head nozzle at up to 200 Hz.  The ChIP only operates in start/stop mode 
and, as a result, printing can take significantly longer compared to the Portrait.  
For example, printing a grid pattern of spots with 250 μm center-to-center 
spacing covering 1 cm2 would take approximately 6 min. with the ChIP compared 
to 2 min. with the Portrait.  In flyby mode the printing time for a given area using 
the Portrait is constant, regardless of the spot to spot distance, because the 
stage motion is constant and the drop ejection frequency is varied.  Because the 
ChIP only operates in start/stop mode, the printing time for a given area using 
this instrument will increase as the spot-to-spot distance decreases.  Therefore, 
the major advantage of the Portrait is speed and the ability to use high matrix 
concentrations.  Although the nozzle-free setup circumvents the risk of clogging, 
it allows the droplets to follow a slightly more variable trajectory onto the sample 
target resulting in slightly decreased accuracy and precision.  The major 
advantage of the ChIP is that the nozzle based ejection provides a well-defined 
droplet trajectory onto the sample resulting in a high precision and high accuracy 
placement  Also, the drop size on the ChIP is around half that of the Portrait, 
which enables arrays to be printed with closer spacing without droplet pooling.  
However, the piezoelectric droplet ejection parameters on the ChIP, such as 
voltage and pulse timing, can vary greatly between different solutions and tuning 
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can be very tedious.  Furthermore, the nozzle can easily become clogged due to 
matrix crystallization and/or contaminants present in the matrix solution resulting 
in erratic drop ejection 
In the experiments reported in this work, the ChIP was used for 
developing the in situ digestion method and the Portrait was used for applying 
this method to the lung cancer FFPE-TMA samples.  As discussed in further 
detail in the following chapters, the robotic spotters are integral to this work. This 
is because when printing enzyme and matrix solutions, it is extremely important 
that precisely the same volume of solution is deposited at each position to ensure 
the resulting protein digestion is accurately representative of the protein content 
at each position. 
  
Instrumentation 
 The most commonly used IMS platform is the MALDI-TOF mass 
spectrometer.  Several other types of instruments including ion trap, FT-ICR, q-
TOF, ion mobility, and DESI mass spectrometers have been used to perform 
imaging experiments and more information on these can be found in several 
recent publications.26, 35, 36  The research presented in this work was performed 
using a MALDI-TOF and MALDI-TOF/TOF MS and therefore these will be the 
focus of the introduction. 
 MALDI, as it is currently used, was first reported by Karas and Hillenkamp 
in 1987.37  In this seminal work, the matrix effect for enhancing the laser 
desorption ionization (LDI) of nonvolatile compounds was demonstrated using an 
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organic acid (nicotinic acid) that exhibited strong resonance absorption at the 
wavelength of the laser used.  The ability of MALDI to produce high mass ions for 
mass spectrometry has led to its application in a broad range of biomolecular 
analyses including proteomics38, oligonucleotides39, 40, polysaccharides41, 
glycoproteins42-44, and synthetic polymers45, 46.   
Despite the widespread use of this technology, the exact role of the matrix 
is not fully understood.  However, three key functions of the matrix were 
proposed in early papers47: 1) incorporation of the analyte molecules into the 
matrix crystals; 2) a collective laser absorption and desorption event; 3) analyte 
ionization through matrix interaction.  Current models describing the UV-MALDI 
ionization mechanism are based on a 2-step framework involving an initial 
(primary) ion formation followed by ion-molecule reactions in the 
desorption/ablation plume that give rise to secondary ions.  Several reviews are 
available which discuss these mechanisms in detail.47-50   
 The MALDI-TOF ionization/mass analyzer combination is well-suited for 
IMS for several reasons.  Most importantly, the duty cycle of the TOF mass 
spectrometer is ideal to be coupled to the pulsed laser process of MALDI. 
MALDI, which uses laser ablation to carry out desorption/ionization of analytes, 
can be carried out at high repetition rates (up 5 kHz) due to the short pulse 
widths of solid state lasers (e.g. Nd:YAG) and the availability of high speed 
instrument electronics.  This pulsed configuration provides enhanced sensitivity 
as compared to a scanning mass analyzer, such as an ion trap, because all ions 
are detected virtually simultaneously in each laser pulse.  Other reasons 
 14 
 
including a wide detectable mass range, high ion transmission efficiency, and 
simplicity in instrument design and maintenance make MALDI-TOF instruments 
ideal for most imaging experiments.  
 In MALDI-TOF instruments, ions formed following each laser pulse are 
accelerated by an electric field to the same kinetic energy into a field free drift 
region.  Ions of different m/z values are separated according to differences in 
their resulting velocity, based on the equation: 
 
where T is time-of-flight, m is mass, q is charge, and k is proportionality constant 
related to instrument dimensions and operating potentials.  Therefore, for two 
ions with the same charge but different masses, the ion with the smaller mass 
will travel at a higher velocity than the one with the larger mass resulting in a 
separation in space and subsequent time of detection, as illustrated in Figure 3.  
Through instrument calibration using a set of standards these times can be 
accurately converted to precise m/z values.     
 Several important developments in the MALDI-TOF MS instrument design 
over the past two decades have enhanced the quality (resolution/sensitivity) of 
data that can be acquired using these instruments.  The development and 
implementation of high-speed computers and electronics have undoubtedly 
played a major role in these improvements, but the most significant technological  
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advancements are the development of delayed extraction 51-53 and the reflectron 
(ion mirror)54.   
Delayed extraction functions by introducing a time delay between the 
ionization and acceleration steps.  The desorption process in MALDI results in a 
distribution spread of the kinetic energies of the resulting ions.  When a 
considering a collection of ions with the same m/z (isobaric), the ions ejected 
from the sample surface with greater kinetic energy have a higher velocity and 
therefore travel farther from the sample surface prior to application of the 
accelerating potential.  Those ions ejected with less kinetic energy, and therefore 
decreased velocity, will be positioned closer to the target surface.  Upon 
application of the accelerating voltage, ions closer to the target surface will 
experience a greater accelerating potential relative to the ions farther from the 
surface.  With the appropriate delay time, the slower ions will obtain enough 
additional potential energy to account for the positional discrepancy and as a 
result all of the ions will be focused at a certain plane in space (such as the 
detector or entrance to the reflectron).  Additionally, delayed extraction allows for 
the plume (ions + neutrals) to expand prior to extraction therefore reducing the 
number of collisions that occur between the accelerating ions and the relatively 
immobile neutral molecules once the voltage is applied. 
 A reflectron consists of a series of evenly spaced electrodes at the end of 
the linear flight tube.  An electric field gradient of the same polarity as the ions is 
applied across the reflectron and therefore upon entry into the reflectron, ions are 
decelerated to zero velocity and then reaccelerated in the opposite direction 
 17 
 
towards the reflectron detector.54  This has a two-fold effect on improving mass 
resolution: first, the effective length of the flight path is increased, and, second, 
the flight paths of ions with the same m/z but different kinetic energies are altered 
such that those with higher kinetic energy penetrate deeper into the reflectron, 
increasing their flight time relative to the slower ions and therefore focusing the 
timing at which the ions reach the detector.54       
 For protein imaging (> m/z 3000) the TOF MS is typically operated in 
linear mode (Figure 3), which provides a wide functional mass range of detection 
and high sensitivity.  For lower molecular weight species (< m/z 3000), the TOF 
MS is operated in reflectron mode (Figure 4), which uses an ion mirror, or 
reflectron, to compensate for the initial velocity/energy distribution and 
significantly improves mass resolution.  
 A MALDI-TOF/TOF instrument55 (Ultraflex III; Bruker Daltonics; Bremen, 
Germany) can be used to generate tandem MS data on ions directly from a 
tissue sample.  In this instrument, ion fragmentation occurs through a mechanism 
called post source metastable decay.  Ions generated by MALDI can naturally 
undergo metastable decay through unimolecular decomposition, resulting in 
single or double backbone cleavages as illustrated in Figure 5.56   
The MALDI-TOF/TOF instrument has the same basic design of a 
reflectron mass spectrometer, but it uses several additional components to 
facilitate ion fragmentation and subsequent detection as a tandem MS spectrum. 
 18 
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Following ion formation and acceleration to 8 kV, all ions have a velocity 
corresponding to E=1/2mv2.  The fragments that form post acceleration through 
metastable decay maintain the velocity of the corresponding precursor forming 
an “ion family”.  A timed ion selector (TIS) is placed in the flight tube and is used 
to select only the precursor ion of interest, as shown in Figure 6.  This is 
achieved by applying a potential across the flight path to deflect all of the passing 
ions other than the precursor.  At the precise timing when the selected precursor 
ion is present in the TIS the potential difference across the TIS is brought to zero 
and the ion family continues to traverse the flight tube unimpeded.     
The selected ion family leaves the TIS and enters the LIFT device to 
undergo velocity focusing and further acceleration.  The LIFT device is 
comprised of four electronic grids with 3 stages of operation.  In stage 1, the 
potential energy of the selected ion family is rapidly lifted, hence LIFT, an 
additional 19 kV.  As the ions enter stage 2, which is held at 19 kV as well, they 
continue to travel at the same velocity and the potential on the third grid is then 
reduced by 2-3 kV.  This accelerates the ions towards Stage 3 where the ions 
are then accelerated to full speed by dropping the voltage on the fourth grid to 
ground (analogous to delayed extraction in a regular MALDI ion source)  and 
time-focused onto the detector as illustrated in Figure 7. 
 An additional device called a post lift metastable suppressor (PLMS) is 
placed between the LIFT cell and the reflectron.  The PLMS is similar in design 
and function to the TIS and serves to deflect the remaining intact precursor ions 
leaving the LIFT cell.  This helps to eliminate undesired fragment ion formation  
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post-acceleration into the second TOF, which can cause significant chemical 
background noise in the fragmentation spectrum.   
 The fragment ion spectra acquired using a MALDI-TOF/TOF resembles 
those generated using other instruments, such as an ion trap, in that the major 
ions detected are a, b, and y ions.  Interpretation of these spectra is carried out 
using commercial software which generates a proposed amino acid sequence 
based on the detected fragments and precursor ion mass.  This sequence is then 
searched against a protein database to determine the representative intact 
protein.   
 
Data Processing and Analysis 
 IMS experiments often result in very large datasets consisting of several 
thousand mass spectra, each of which contains hundreds of peaks.  There are 
several software packages that can efficiently manage IMS data and these 
programs automate several functions including setup and acquisition, spectral 
processing, image generation, and statistical analysis. 
 Following acquisition, several spectral processing steps are typically 
carried out including baseline subtraction, smoothing, peak picking, and 
normalization.  Baseline subtraction uses an iterative algorithm to remove the 
baseline slope and offset that is caused mainly by background chemical and 
electronic noise.  Smoothing a mass spectrum averages neighboring data points 
to increase the signal/noise ratio and enhance the peak shapes.  Peak picking 
algorithms analyze the data points in a spectrum and differentiate peaks 
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corresponding to real analyte ions from those attributed to noise and background.  
Thresholding parameters, such as a S/N cutoff value, are typically used to control 
and limit the peak selection process.  In reflectron mode, the TOF MS is capable 
of resolving the isotopes of an individual peptide or lipid species, which naturally 
result from the presence of one or more 13C atoms (Figure 4).  Peak picking 
algorithms, such as the SNAP algorithm developed by Bruker Daltonics, are able 
to recognize these isotopic clusters and assign a representative mass only to the 
monoisotopic peak, which is the peak from the molecule containing only 12C 
atoms and no 13C atoms.  This can be an extremely important step in processing 
peptide and lipid spectra, because it results in a significant reduction in data 
complexity.  For statistical analysis, monoisotopic peak picking generates a 
single peak to represent each biomolecule, as opposed to several isotopes, and 
can be used as the comparative value.    
 Another important aspect of data processing is spectra normalization.  
This is typically carried out by evaluating the total ion current (TIC) of all spectra 
in a dataset.  The TIC is defined as the sum of the intensities of all data points in 
a spectrum.  Notwithstanding certain assumptions, it is expected that this value 
should be similar between all spectra in a dataset.  Deviations in the TIC likely 
result from slight day-to-day fluctuations in instrument performance, variations in 
sample preparation, and differing chemical microenvironments in tissues.  When 
normalizing on a spectrum to spectrum basis, all data points are adjusted by the 
same increment so that the resulting TIC of each independent spectrum is equal 
to a normalized value.   
 25 
 
 Other normalization functions are also used, including the division of each 
data point in a spectrum by the TIC of the entire spectrum to bring all data point 
values within the range of [0,1].  This type of normalization is independent of the 
other spectra in a dataset, because each data point is essentially normalized 
based on its relative contribution to the TIC.    
 
Biological Applications of IMS 
 Over the past decade IMS and direct tissue profiling experiments have 
been conducted on a wide variety of biological samples and have provided 
investigators with valuable insight into the underlying biology.  IMS has the ability 
to provide a comprehensive view of a subset of a tissues proteome in an 
extraordinarily short amount of time.  As a result, examining the differences 
between a set of normal and diseased tissues is a particularly useful application 
of this technology. For example, IMS has been used to examine the proteomic 
changes involved in the development and progression of numerous cancers 
including gliomas13, 57, 58, breast cancer59, 60, prostate cancer61, 62, colon cancer63, 
and lung cancer64, 65.  These experiments revealed numerous differential protein 
expression patterns between cancerous and normal tissues.   
 Recently, Caldwell et al.66 examined soft tissue sarcomas using IMS and 
determined that tissue adjacent to the tumor that appeared histologically normal, 
actually exhibited changes at the molecular level consistent with the cancerous 
regions.  These tumor associated proteins showed a gradient effect across the 
histologically defined tumor margin into the normal tissue at distances up to 1.5 
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cm.  A larger study that performed a similar analysis on tumors from patients with 
clear cell renal cell carcinoma showed comparable results (Stacey R. 
Oppenheimer, Unpublished Data).  Statistical analysis of the data revealed 
several interesting patterns, including proteins that dropped off sharply at the 
margin, those that extended beyond the tumor margin into the normal, and those 
that appeared only in the normal.  These results demonstrate that changes are 
likely taking place at the molecular level that cannot be detected using 
histopathological analysis alone.  The implications of this are important not only 
from a cancer biology perspective, but also in the context of surgical removal of 
tumors.  For example, during the surgical removal of tumors it is imperative that 
all cancerous cells are removed in their entirety to improve a patient’s chance of 
survival and prevent local recurrence.  This data suggests that cancer cells may 
be invasive beyond the histological tumor margin and could likely play a role in 
tumor recurrence at these sites. 
Other research has focused on the use of mass spectrometry data 
acquired through imaging and profiling studies to differentiate and classify 
different tissue histologies.  For histological classification, pathologists typically 
use light microscopy to examine cellular morphology and various antibody stains 
to assess the presence or absence of histology specific proteins.  The advantage 
of incorporating IMS into this workflow is that the spatial distribution of hundreds 
of protein species can be visualized simultaneously, adding an extraordinary 
amount of additional information. 
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 Histology directed imaging and profiling refers to the application of IMS to 
the molecular analysis of targeted regions of clinical samples.  In this workflow, a  
pathologist reviews a tissue section serial to the section used for MS analysis to 
determine specific areas of interest.67  In-house software was developed to guide 
the MS analysis to only acquire mass spectra from these pathologically relevant 
regions, which can significantly reduce the overall time of the MS analysis by 
analyzing only specific regions of interest.67  Furthermore, each mass spectrum 
can be directly associated with a specific histological region.   
Rahman et al. applied this workflow to lung cancer tissues and were able 
to classify normal epithelium, pre-invasive, and invasive lung lesions with 90% 
accuracy based on proteomic differences.68  Additionally, Schwartz et al. showed 
that this technology could effectively classify the grade of different human 
gliomas and predict survival of the patients.69   
 
Summary and Research Objectives 
 Biological systems are extremely complex and new tools are necessary to 
effectively enhance our knowledge and understanding of their underlying 
mechanisms.  Mass spectrometry has proven to be an essential technology for 
the analysis of biological samples due to its unparalleled throughput, sensitivity, 
and specificity.  IMS combines the power of MS with the inherent spatial 
information contained in a biological sample revealing biomolecular distributions 
on a scale unattainable by other techniques.    
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 The work presented here has two main focuses.  First, chapter 2 details 
the development of a method to carry out in situ chemical reactions to enhance 
the proteomic information that can be detected in a tissue sample.  This method, 
referred to as in situ digestion, uses an enzyme to digest the proteins present in 
discrete regions of a tissue prior to matrix application and MS analysis.  The 
enzymatically digested proteins result in a large collection of proteolytic peptides 
in the range of m/z 700-3000.  This collection of peptides can be sequenced and 
identified directly from the tissue using tandem MS and then linked back to their 
respective intact protein.  The spatial information for these ions can be used to 
validate their identification because all peptides from the same protein should 
exhibit the same spatial distribution.  In situ digestion also enables the indirect 
detection of high molecular weight proteins (> m/z 30,000) that are not detected 
in a standard protein imaging experiment by mapping the peptides generated 
from these species.  Finally, this method enables the analysis of formalin-fixed 
paraffin-embedded (FFPE) tissues.  FFPE tissues are a valuable and extensive 
source of clinical samples which are not compatible for use in standard protein 
imaging experiments.   
 Second, chapters 3 and 4 detail the application of this method to FFPE 
lung cancer tissue microarrays (TMA).  We show that in situ digestion coupled 
with imaging mass spectrometry can be used to reproducibly map numerous 
protein species in a large population of lung cancer patients.  Several of these 
proteins correspond to previously reported markers of lung cancer, while others 
have not yet been associated with this disease.  Furthermore, we discovered 
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patterns of protein expression that can be used to accurately distinguish and 
classify the histological subtypes present in the sample cohort.   
In summary, this work shows that when IMS is performed on a large set of 
tissues in parallel with a pathological evaluation, the combined histological and 
molecular information provides a depth of information that has the potential to 
revolutionize disease diagnosis, prediction of prognosis, and course of therapy. 
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CHAPTER II 
 
 
 
 IDENTIFICATION OF PROTEINS DIRECTLY FROM TISSUE: IN SITU 
TRYPTIC DIGESTIONS COUPLED WITH IMAGING MASS SPECTROMETRY 
 
 
 
Abstract 
 
 A novel method for on-tissue identification of proteins in spatially discrete 
regions is described using tryptic digestion followed by MALDI Imaging Mass 
Spectrometry (IMS) with MS/MS analysis.  IMS is first used to reveal the protein 
and peptide spatial distribution in a tissue section and then a serial section is 
robotically spotted with small volumes of trypsin solution to carry out in situ 
protease digestion.  After hydrolysis, matrix solution is applied to the digested 
spots with subsequent analysis by IMS to reveal the spatial distribution of the 
various tryptic fragments.  Sequence determination of the tryptic fragments is 
performed using MALDI MS/MS analysis on-tissue directly from the individual 
digest spots. This protocol enables protein identification directly from tissue while 
preserving the spatial integrity of the tissue sample. The procedure is 
demonstrated with the identification of several proteins in coronal sections of a 
rat brain. 
 
Introduction 
 Desorption of proteins and subsequent analysis by MALDI MS provides a 
measurement of molecular weight, but not the identification of the protein.  
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Protein databases do not generally include the sometimes extensive post-
translational modifications of most proteins: indeed such modifications are still 
unknown in most cases.  Further, nominal molecular weight redundancies to 
within the mass measurement accuracy of the experiment can be problematic. 
Current protein identification techniques are based on extraction, proteolysis, and 
LC/MS/MS techniques.  Although these procedures are effective, they can be 
tedious, require relatively large amounts of sample, and result in loss of spatial 
information.  Nonetheless, this procedure remains an effective means of 
identification of an unknown peak in a spectrum.  Several recent papers have 
attempted to address some of these problems through automation.  For example, 
a molecular scanner approach involving tissue blotting onto a trypsin membrane, 
followed by capture of the resulting peptides onto a second membrane can be 
used to digest proteins while maintaining some degree of spatial resolution 70-72.  
In addition, several studies 73-82 have reported MS/MS data directly obtained from 
tissue samples. 
 In the current work, we show that automated deposition of a trypsin 
solution can be effectively used to carry out digestion of proteins and peptides 
directly on thin tissue sections in well-defined micro-spotted arrays.83  These 
arrays can then be automatically spotted with matrix solution for subsequent 
MALDI MS and MALDI MS/MS analyses to obtain sequence information for the 
tryptic peptides and thereby enable protein identification.  The array printer used 
for reagent deposition ensures accurate and precise droplet placement to enable 
well-controlled and reproducible digestion conditions and is an essential part of 
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the process.  Confining the digestion enzyme to within discrete spots on the 
order of ~200 μm in diameter reduces the complexity of the analysis because the 
proteins digested are representative of only a limited number of cells and 
extracellular space.  Spotted arrays have been found to be much more 
reproducible and compatible with automation than spray coating and other matrix 
deposition techniques 84.  Individual droplet placement allows for a micro-
extraction process to occur on the tissue surface at each position over several 
deposition iterations.  This enhances the efficiency of the protein digestion and 
subsequent matrix crystallization process, thereby improving sensitivity and 
signal quality.  The bilateral symmetry of the coronal brain sections used in this 
report provide a measure of the reproducibility of the spot-to-spot digestion 
efficiency, since the relative intensity of the tryptic peptides generated from the 
proteins present in the substructures of each hemisphere should be equivalent.   
The novel aspect of this technique lies in its capability to not only visualize, but to 
also identify proteins from discrete areas of a tissue section encompassing areas 
of about 200 μm diameter.  This technique is optimal for the verification of protein 
identities where specific proteins are suspected to be present.  In these cases, 
the digest spot can be searched for known tryptic fragments of a protein and the 
peptide sequenced by MS/MS if found.  The ability to robotically carry out 
controlled and reproducible trypsin digestions within thousands of discrete spots 
throughout a tissue section enables positive identification of numerous protein 
species with high spatial localization and a relatively small amount of sample 
preparation and time requirement.   
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 The advantage of this method over traditional protein visualization 
techniques, such as immunohistochemical staining, is that in a single analysis it 
is possible to examine the distribution of numerous proteins and peptides while 
simultaneously obtaining in situ identification.  The digest data can be examined 
in parallel with the information generated by the peptide and protein imaging 
experiments to provide a comprehensive analysis of a tissue section.  This 
approach is ideal for discovery since it does not require specific reagents for 
molecular detection (such as an antibody). 
 
Results 
 The spectra generated at each spot on the digested tissue typically 
contain several hundred distinct peaks with a S/N > 5 (Figure 8).  The signal 
intensity of the tryptic peptides vary widely due to several factors, i.e. different 
expression levels of proteins, variations in digestion efficiency, and differences in 
desorption and ionization efficiencies of different peptides.  Nevertheless, clearly 
resolved molecular species are easily identified in these digest spectra as shown 
in the inset in the upper left of Figure 8.  Myelin basic protein (MBP), which is 
expressed regionally in the brain at relatively high levels and is essential for the 
formation of central nervous system (CNS) myelin and neuronal transmission 85, 
was among the proteins identified using the workflow shown in Figure 9.  There 
are several molecular forms of MBP expressed in the CNS including a number of 
splice variants and numerous post translational modifications 85. The major 
isoform in adult rats has been reported to have a molecular weight of 14.2 kDa 85.   
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The distribution of this intact protein was determined using IMS on a coronal 
section of rat brain tissue as shown in Figure 10.  After digestion, a total of 8 
tryptic peptides from MBP were detected (Figure 11) and sequenced directly 
from the tissue (Figure 12).  Other tryptic peptides were also generated and 
detected from MBP, although it was not necessary to sequence them since there 
was already sufficient data for a high confidence identification of this protein.  
Proteins identified in this way were further validated by comparison of the spatial 
distribution of a given parent protein with sequenced peptides generated from 
that protein.  Internal calibration of the acquired spectra using the masses of 
trypsin autolysis fragments as well as several other known tryptic peptides 
sequenced with high confidence through MS/MS from proteins present 
throughout the rat brain were used to achieve mass accuracies of about 10 ppm.   
As expected, the MBP tryptic peptides show an ion density distribution consistent 
with that of the intact protein.  It is noted that other isoforms of MBP were present 
in the protein analysis at lower intensity. 
 As further examples, other proteins identified in the same process from a 
different region of a rat brain include neurogranin, a 7496 Da brain-specific 
protein kinase C (PKC) substrate 86 and brain-specific polypeptide (PEP-19), a 
6676 Da neuron specific protein 87 (Figure 13).  Each of the four tryptic peptides 
displayed for each protein were sequenced by MS/MS and linked to their 
respective parent protein through database matching and spatial distribution 
correlation.  Neurogranin was distributed with highest intensity throughout the 
cerebral cortex and with a lesser intensity in the striatum, which is in accordance 
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with the findings of Represa et al. 86 who examined the distribution of this protein 
in the adult rat brain through immunohistochemistry.  PEP-19 is shown to be 
distributed with highest intensity throughout the striatum, and with lower 
intensities in the globus pallidus.  These findings also correlate well with previous 
studies that have determined, through immunohistochemistry, that PEP-19 is 
highly expressed in the basal ganglia 87.  These data further demonstrate the 
ability of this method to confidently identify proteins using both digest and MS/MS 
data in parallel with IMS.  The data obtained for the identification of these three 
proteins is summarized in Table 1.        
 An initial step in these experiments involves determination of peptides 
present throughout the tissue prior to digestion.  This not only provides a higher 
level of confidence in assessing those peaks in the digest spectra as being 
generated from proteolysis, but also provides information about the presence of 
endogenous peptides in different regions of a tissue.  For example, the structure 
of the globus pallidus, which is a major element of the basal ganglia system, can 
be distinguished in the native peptide image from several ion density maps of the 
in vivo processing products of the proenkephalin A precursor into its propeptide 
and active peptide forms (Figure 14).  The propeptide corresponding to the 143-
185 region of this protein is detected in the non-digest analysis at m/z 4594.  
Digestion of this peptide generates several tryptic fragments including m/z 
2619.24 and 2818.37 which are detected in the digest images and lie in a mass 
range more amenable to MS/MS analysis.  Several of these peptides do not 
contain lysine or arginine residues and therefore do not undergo digestion from  
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the trypsin enzyme.  Consequently, although these peaks are detected in the 
digest spectra, they can be categorized as non-tryptic peptides. 
Signals corresponding to only a few pixels in the ion maps can be used to 
characterize species localized to isolated regions of a tissue section.  For 
example, Arg-vasopressin and copeptin, two peptide hormones generated from 
the processing of the vasopressin-neurophysin 2-copeptin precursor, were 
detected solely in the supraoptic nucleus, which is consistent with previous 
studies 88.  Mass spectra acquired at this position in the non-digest analysis 
indicate that this precursor is fully processed in this region due to the presence of 
the active form of Arg-vasopressin as shown in Figure 15.  The calculated mass 
of Arg-vasopressin is 1086.44, yet experimentally it is detected in this region with 
a mass of 1083.44.  As previously described 89, this mass shift suggests that the 
C-terminus glycine is amidated and the disulfide bond is intact, the latter of which 
was further confirmed in the present study by MS/MS analysis.  The calculated 
mass of copeptin is 4281.80 Da, yet it has been shown that this peptide is N-
glycosylated 90-92 at an asparagine residue. Two tryptic peptides found at m/z 
1798.96 and 2061.09 corresponded to the 21-37 and 21-39 regions, respectively, 
of the non-glycosylated segment of the copeptin sequence.  These peptides were 
sequenced by MS/MS on a digested tissue section to confirm the sequence.  Ivell 
et al. used tritium labeled sugars to determine that the glycosylation side chain 
on copeptin contained mannose, glucosamine, and fucose 93. A peak found at 
m/z 5930 in the non-digested image is localized to the supraoptic nucleus, 
identical to that of Arg-vasopressin.  This corresponds to a mass shift of 1648.5  
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Da from the calculated mass of copeptin, which is consistent with a carbohydrate 
chain composed of Man3GlcNAc5Fuc1.  This mass shift is also apparent in the 
digest analysis on the copeptin tryptic peptides consisting of residues 1-20 and 1-
15, both of which contain the glycosylated residue. Application of trypsin followed 
by treatment with peptide N-Glycosidase F (PNGase F) to the posterior region of 
a rat pituitary section where copeptin is stored 94, resulted in removal of this 
polysaccharide chain and the tryptic peptides from residues 1-20 and 1-15 were 
detected at their expected masses.  Intact copeptin was also detected at its 
expected mass in a section treated only with PNGase F.       
 Tryptic peptides from the digestion of higher molecular weight proteins 
including actin, a 41 kDa globular structural protein, tubulin, a 55 kDa protein 
which dimerizes to form microtubules, and synapsin-1, a 74 kDa neuronal protein 
were identified using this method (Figure 16).  Generally, low abundance 
proteins within the m/z range of these relatively high molecular weight species 
are difficult to analyze using MALDI-TOF MS.  Proteolysis of these high 
molecular weight proteins directly on tissue and image analysis of unique 
peptides enables visualization of their distribution throughout a tissue section.   
 
Discussion 
 MALDI IMS is a unique tool for analyzing the spatial distribution of 
peptides and proteins throughout tissue sections, providing an enormous amount 
of data with minimal sample preparation time.  Molecular analysis directly on-
tissue for identification of specific proteins offers an alternative to the time 
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consuming separation and labeling steps commonly used in proteomics with the 
advantage of preserving the spatial distribution of the detected species.   
Technological advancements in instrumentation including high speed 
electronics, solid state lasers with high repetition rates, enhanced computer 
processing capabilities, and unique imaging software, continue to make this 
technology more practical and capable.  The development of automated devices 
for sample preparation 84, 95 has enabled accurate and precise reagent deposition 
onto microscopic regions of a tissue sample.  The ability to digest these protein 
species and carry out MS/MS analysis directly on tissue allows one to achieve 
protein identification with high confidence within localized regions of a tissue 
section without separation or homogenization.  The consistent ion intensities 
within and between separate images indicates that well-controlled and 
reproducible digestion has been achieved, providing an increased confidence in 
comparative studies.  Digestion also presents possibilities for the detection of 
certain high molecular weight proteins which are not easily detected in MALDI 
experiments due to their low abundance and poor ionization and detection 
efficiency in this mass region.   
 The identification of proteins directly from tissue combining in situ 
digestion and MALDI MS is most effective in the validation process, i.e., verifying 
the presence of a protein whose I.D. has either been previously established in 
other like tissues or is tentatively assigned due to known biology or from other 
data.  The process consists of 5 steps: 1.) establishing the distribution of one or 
more proteins by molecular weight using imaging MALDI MS, 2.) tryptic 
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hydrolysis of discrete spots where proteins of interest are located, 3.) acquiring 
mass spectra from these digested spots using MALDI MS, noting those peptides 
that correlate with the theoretical peptides that should be generated from a given 
protein or proteins, 4.) MS/MS sequence analysis and protein database matching 
for identification of the proteins, and 5.) correlation of the images for each tryptic 
peptides to that of the intact protein in the tissue specimen.  
 Although the proteins identified in this work are generally expressed at 
high abundance, current work towards further optimization of the current protocol 
is focused on the analysis of lower abundance proteins.  For example, the time 
dependence of on-tissue digestions is an area of much interest that needs further 
investigation.  Ericsson et al.96 have shown that the downsizing the enzymatic 
digestion process to nL volumes results in a decrease in the time required to 
achieve sufficient digestion due to a decrease in the diffusion distance between 
the enzyme and substrate.  A systematic study will need to be performed to 
determine optimal spotting conditions for digestions that vary enzyme 
concentration, time, volume, and solvent composition.  Other steps such as 
denaturing of proteins and reducing cysteine-cysteine disulfide bonds prior to 
digestion could result in more complete digestion.  Additionally, other enzymes or 
combinations of enzymes could be applied to tissues in an effort to carry out 
more targeted analyses for specific proteins.  For example, Figure 17 shows the 
distribution of three peptides identified from myelin basic protein in separate rat  
brain sections using three different proteases: trypsin, chymotrypsin, and 
subtilisin.  For the analysis of complex mixtures such as a protein digest, Fourier 
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transform ion cyclotron resonance mass spectrometry (FTICR-MS) will be of 
significant advantage in resolving species in these samples by providing high 
mass accuracy information.   
 On-tissue proteomic technologies present enormous potential for the 
discovery of new protein and peptide species, or modifications of those already 
known, since it does not require protein-specific reagents such as antibodies.  
The protocols and technology cited in this paper offer a viable alternative to 
tissue extraction and separation procedures that nicely complements traditional 
protein identification and characterization techniques.  By combining the 
extensive amount of data obtained from each of the protein, peptide, and digest 
imaging experiments, it is possible to carry out an in-depth characterization of a 
tissue for those proteins amenable to this process.  We believe analysis of a 
tissue in this manner will prove essential in studying disease because it enables 
the tissue to be examined in its native state.  
 
Materials and Methods 
Material.  HPLC grade methanol, trifluoroacetic acid (TFA), glacial acetic acid, 
and reagent grade ethanol were purchased from Fisher Scientific (Pittsburgh, 
PA).  DHB (2, 5-Dihydroxybenzoic acid, 99% purity) was purchased from Acros 
Organics (New Jersey, USA) and used without further purification.  Sinapinic acid 
(3, 5-dimethoxy-4-hydroxycinnamic acid, 99% purity) was purchased from Fluka 
(Buchs, Switzerland) and used without further purification.  Trypsin Gold was 
purchased from Promega (Madison, WI) and diluted in 200 μL of 50 mM acetic 
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acid to obtain a final concentration of 0.5 μg/μL  for the stock solution.  A 40 μL 
aliquot of this stock solution was activated by adding 200 μL of 100 mM 
ammonium bicarbonate to reach a pH of ~8 and a final trypsin concentration of 
0.083 μg/μL.   Peptide: N-Glycosidase F (PNGase F) was purchased from New 
England BioLabs (Ipswich, MA).  
 
Tissue Preparation.  Brains and pituitary glands from adult Sprauge-Dawley rats 
were dissected and stored at -80º C until analysis.  Thin (12 μm) tissue sections 
were prepared and thaw mounted onto a gold plated MALDI target using a 
procedure described by Schwartz et al.27.  The targets were placed in a 
desiccator for 30 min to allow the tissue sections to dry and equilibrate to room 
temperature.  Tissue fixation and removal of salts and other contaminants was 
carried out through a series of ethanol/water wash steps as described by Aerni et 
al.84  An additional final tissue wash step similar to that described by Kutz et al. 76 
was used which consisted of submersion of the tissue sections into a solution of 
90% ethanol, 9% glacial acetic acid, and 1% deionized water for 30s.  The tissue 
sections were then dried and stored in a vacuum desiccator until analysis.   
   This tissue preparation procedure removes interfering species, such as 
salts and phospholipids, that can promote adduct formation, ion suppression, and 
poor matrix crystallization.  Additionally, signals generated from the 
phospholipids on an un-washed tissue section may result in significant spectral 
interference with low molecular weight tryptic peptides. 
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Imaging Mass Spectrometry of Proteins and Peptides.    A piezoelectric 
based chemical inkjet printer (ChIP-1000, Shimadzu Co., Kyoto, Japan) was 
used for deposition of both the trypsin and matrix solutions.  A modified sample 
holder was used to place gold coated MALDI plates containing tissue sections 
directly into the robotic printer.  Matrix solutions consisting of 15 mg/mL of 
sinapinic acid in 60:40 ACN:H20 / 0.5% TFA (aq.) for proteins and 25 mg/mL of 
DHB in 50:50 MeOH/H2O / 0.5% TFA (aq.) for peptides were printed onto 
sections serial to the section used for on-tissue digestion.  The arrays of 
approximately 2500 spots consisted of 250 μm  center-to-center spacing and a 
total matrix volume of ~10 nL at each spot was deposited over a series of 20 
iterations at 5 drops per iteration.  The images were acquired using an Ultraflex II 
MALDI-TOF TOF instrument (Bruker-Daltonics Billerica, MA).   
For protein imaging, the mass spectrometer was operated with positive 
polarity in linear mode and spectra were acquired in the range of m/z 1500-
30,000.  For peptides, the mass spectrometer was operated with positive polarity 
in reflectron mode and spectra were acquired in the range of m/z 600-10000.  A 
total of 600 spectra were acquired at each spot position at a laser frequency of 
200 Hz.  Specifically developed software was then used to convert the spectral 
information into image files compatible with Biomap imaging software (Novartis, 
Basel, Switzerland) that was used to visualize ion density maps.   
 
On-Tissue Digestion.  A solution containing 0.083 μg/μL of trypsin was spotted 
onto the rat brain tissue sections using the automated printer in an array 
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incorporating 250 μm center to center spacing between individual spots, each of 
which were approximately 200 μm in diameter.  The trypsin was spotted over a 
series of 30 iterations while depositing 5 drops (100 pL per drop) each iteration to 
achieve a total spot volume of 15 nL (5 drops of the trypsin solution were 
deposited at each position in 8 min. time intervals).    Each digest spot appeared 
to dry completely between each subsequent spotting iteration.   The trypsin 
spotting proceeded at room temperature (~21 °C) over a time period of ~4 h, 
allowing ample time for digestion to take place.  Following digestion, a solution 
consisting of 25 mg/mL of DHB in 1:1 methanol/0.5% TFA (aq). was spotted 
directly onto the array of tryptic spots over 20 iterations at 5 drops per iteration to 
give a total matrix spot volume of 10 nL.   
 
Imaging Mass Spectrometry and MS/MS of Digested Tissue Section.  The 
printed arrays were analyzed using a Ultraflex II MALDI-TOF TOF equipped with 
a smart beam laser97 and controlled by the Flex Control 2.4 software package.  
The mass spectrometer was operated with positive polarity in reflectron mode 
and spectra acquired in the range of m/z 500-6000.  A timed ion gate was used 
for precursor ion selection and the fragments generated were further accelerated 
with 19 kV in the LIFT cell, and detected following passage through the 
reflectron.  Image acquisition of the spotted arrays was carried out using the Flex 
Imaging 1.1 software package.  A total of 1350 spectra were acquired at each 
spot position in a customized spiral raster pattern in 50 shot increments at a laser 
frequency of 200 Hz.  The customized spiral raster pattern was used to 
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accommodate any edge-biased crystal formation characteristic of DHB matrix 
spots that may have occurred. Ion images were created as described above. 
 
Glycopeptide Analysis.  The posterior region of a 12 μm section of a rat 
pituitary gland was spotted 3 consecutive times with 500 nL of a 0.083 μg/μL of 
trypsin using a micropipette, with each drop being allowed to dry before spotting 
the next.  Next, 500 nL of the amidase PNGase F was spotted 3 consecutive 
times at a concentration of 500,000 U/mL directly onto the trypsin spots, with 
each spot being allowed to dry before placing the next.  Upon drying, 2 drops of 
500 nL DHB in 1:1 methanol/0.5% TFA (aq). were deposited at these positions 
and the tissues were analyzed using a Ultraflex II MALDI-TOF TOF.      
 
Data Analysis.  The MS/MS spectra generated were submitted into a MASCOT 
(Matrix Science, Boston MA) database search engine to match tryptic peptide 
sequences to their respective intact proteins.  The MS/MS spectrum search was 
performed with a peptide tolerance of ± 0.3 Da and a fragment tolerance of ± 0.5 
Da.  The search criteria also included up to 2 missed cleavages and variable 
modifications including lysine acetylation, N-terminus acetylation, C-terminus 
amidation, and methionine oxidation. 
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CHAPTER III 
 
 
 
HIGH-THROUGHPUT PROTEOMIC ANALYSIS OF FORMALIN-FIXED 
PARAFFIN-EMBEDDED TISSUE MICROARRAYS USING MALDI IMAGING 
MASS SPECTROMETRY 
 
 
 
Abstract 
 
 A novel method for high-throughput proteomic analysis of formalin-fixed 
paraffin-embedded (FFPE) tissue microarrays (TMA) is described using on-tissue 
tryptic digestion followed by MALDI imaging mass spectrometry.  A TMA section 
containing needle core biopsies from lung tumor patients was analyzed using 
mass spectrometry and the data correlated to a serial H&E stained section 
having various histological regions marked including cancer, non-cancer, and 
normal.  By associating each mass spectrum with a defined histological region, 
statistical classification models were generated that can sufficiently distinguish 
adenocarcinoma biopsies from squamous cell carcinoma biopsies.  These 
classification models were built using a training set of biopsies in the TMA and 
were then validated on the remaining biopsies.  Peptide markers of interest were 
identified directly from the TMA section using MALDI MS/MS sequence analysis.  
The ability to detect and characterize tumor marker proteins for a large cohort of 
FFPE samples in a high throughput approach will be of significant benefit not 
only to investigators studying tumor biology, but also to clinicians for diagnostic 
and prognostic purposes. 
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Introduction 
 IMS has been successfully used to identify subsets of markers that 
correlate with cancer progression.65, 67, 69, 98-100  For example, in earlier studies, 
protein markers were obtained from the direct MALDI IMS proteomic analysis of 
glioma biopsies that could differentiate stage including the most aggressive form, 
glioblastoma multiforms, and also with patient outcomes.69 Our laboratory has 
also investigated a large cohort of human non-small cell lung cancer biopsies.65, 
68 In this study, sections from fresh frozen biopsies were cut and spotted with 
matrix on areas identified as cancerous. From the resulting protein profiles, 
statistical analyses identified markers that could be correlated with histological 
assessment and patient outcomes. These patterns precisely distinguished 
healthy versus cancerous tissue, and also distinguished various sub types of 
non-small cell cancer, such as adenocarcinoma, squamous cell carcinoma and 
large cell carcinoma.  Further, these patterns could be correlated with patient 
survival. From this latter cohort, several of the proteins of the survival signature 
were identified. These results highlight the use of this technology for the rapid 
characterization of disease at the protein level to confirm diagnosis and 
potentially aid in therapeutic management.101  
 MALDI IMS is usually carried out on fresh frozen tissue because these 
samples are highly representative of a tissue in its native state. However, the 
vast majority of clinical specimens stored in hospital tissue banks are formalin-
fixed paraffin embedded (FFPE), representing an expansive archive of diseased 
tissues. Formalin fixation stabilizes proteins by inducing chemical cross-linking 
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throughout a tissue section therefore preventing postmortem enzymatic 
proteolysis while maintaining the cellular histology.102  However, the major 
drawback of formalin fixation is that it renders a tissue unsuitable to undergo 
routine biochemical protein extraction and subsequent proteomic analysis.103   
 Over the past two decades, several methods have been reported that 
attempt to reverse formalin-fixation, a process commonly referred to as antigen 
retrieval.104-106 Antigen retrieval typically involves the application of high 
temperature treatment along with the use of a buffer solution, in an effort to 
reverse the protein cross-linking and return a tissue to its native state.104  
Development of methods to effectively and reproducibly carry out antigen 
retrieval on FFPE tissue specimens has allowed for the standardization of IHC 
protocols and has recently opened the door to a vast collection of archival clinical 
samples to be analyzed for genomic and proteomic information. For protein 
identification, approaches using either liquid chromatography coupled to tandem 
mass spectrometry (LC-MS/MS) 106-109 or 2D gel electrophoresis110 have been 
reported. Recently, a 2D gel based study showed that the same proteins can be 
identified independently of the type of preservation used.111  These authors 
reported that when the appropriate antigen retrieval protocol is applied, the level 
of protein identification was found comparable to that of fresh frozen tissues.  
 In order to comprehensively evaluate the diagnostic, prognostic, and 
therapeutic value of gene and/or protein expression in clinical tissue specimens, 
it is necessary to analyze a large number of samples from patients in different 
stages of disease.112 In this regard, tissue microarrays (TMA) were originally 
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developed to facilitate the molecular and pathological analysis of tissues in a 
massively parallel and high-throughput approach.112-114 A TMA consists of a 
paraffin block in which as many as 1000 cylindrical tissue biopsies from individual 
tumors are distributed into a precise array.112 Sections cut from this array enable 
investigation of DNA by fluorescence in situ hybridization (FISH), RNA by mRNA 
in situ hybridization, or proteins by IHC, from each of the biopsy samples.  
 We have developed an IMS method incorporating antigen retrieval and in 
situ enzymatic digestion to analyze the protein content of tissue microarrays 
(TMA) containing FFPE non-small-cell lung cancer (NSCLC) biopsies.115  The 
TMAs used in this study contained various types of non-small-cell lung cancer 
(NSCLC) biopsies including squamous cell carcinoma, adenocarcinoma, and 
bronchioloalveolar carcinoma as well as non-cancer tissue from matched 
individuals.  MALDI IMS was used to analyze these samples in a high-throughput 
fashion providing proteomic data from discrete regions of each biopsy. We 
demonstrate, as previously observed at the protein level from fresh frozen tissue 
65, that a histological classification of lung cancer can be effectively accomplished 
at the peptide level on FFPE tissues. The ability to detect and characterize tumor 
marker proteins for a large cohort of samples in a high throughput approach will 
be of significant benefit not only to investigators studying tumor biology, but also 
to clinicians for diagnostic and prognostic purposes. 
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Results 
 The antigen retrieval protocol used in these studies enables the analysis 
of FFPE tissues using the in situ digest methodology.  Figure 18 shows the 
spectra generated on two serial FFPE TMA sections where one section was 
subjected to the antigen retrieval protocol and the other was not (control).  It is 
clear from these results that antigen retrieval is necessary and effective in 
allowing the enzyme access to the proteins in these tissues.  The spectra 
generated from the section that underwent antigen retrieval shows hundreds of 
tryptic peptide peaks while only trypsin autolysis peaks were detected from the 
control section.  Autolysis refers to the process where the trypsin enzyme begins 
to digest other trypsin molecules.  A small degree of autolysis is expected, as in 
Figure 18 b.), however the excessive amount of autolysis shown in Figure 18 a.) 
is indicative of virtually no proteins being accessible to the enzyme.   
The FFPE TMA analyzed in this study contains 1 mm needle core 
biopsies from lung tumors diagnosed as adenocarcinoma and squamous cell 
carcinoma, as well as adjacent normal control tissue and other NSCLC tumors.  
This study only considers the adenocarcinoma and squamous cell carcinoma 
biopsies due to the limited number of samples for the other cancer types.  The 
layout of the TMA analyzed is such that there are duplicate and, in some cases, 
triplicate needle core punches for several of the biopsies.  Therefore, the TMA 
contains a total of 24 squamous cell carcinoma needle cores from 15 different 
patients (7 unpaired, 7 duplicates, and 1 triplicate) and 19 adenocarcinoma 
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needle cores from 11 different patients (3 unpaired and 8 duplicates) that contain 
cancerous regions and are considered in the study.     
In the discovery and protocol development process, a hematoxylin and 
eosin (H&E) stained section of the TMA was first analyzed using light microscopy 
and the cancer, non-cancer, and normal regions were marked in each biopsy 
based on histology.  Non-cancer regions consist of tissue that is not cancerous 
but is not normal either, including areas of inflammation, scar tissue, etc. The 
cellular regions that were not able to be clearly identified were not marked and 
therefore were not used in the statistical model generation step. This annotated 
tissue section was then co-registered with a serial TMA section analyzed by 
MALDI IMS, (Figure 19), enabling individual mass spectra obtained from each 
coordinate position on the tissue (pixel) to be linked to that same precise 
histological region in the TMA. 
The mass spectrum generated at each spot on the digested tissue 
typically contain many hundreds of peaks with a signal-to-noise (S/N) > 5 (Figure 
20 (a)). The ensemble of tryptic peptides at each position represents a variety of 
proteins with a broad range of functionality and molecular weights. The signal 
intensities of the tryptic peptides are mediated by several factors, i.e. protein 
concentration differences, variations in enzymatic digestion efficiency, and 
differences in desorption and ionization efficiencies.  Nonetheless, mass spectra 
from similar histological regions contain peak profiles with a high degree of 
concordance, demonstrating a consistent and reproducible methodology as 
shown in Figure 21.  This figure illustrates, as expected, that the average spectra 
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generated from the cancer regions of two duplicate biopsies are extremely 
similar.  This reproducibility is further exhibited using a t-test and minimum 1.6-
fold intensity difference comparison for the 200 most intense peaks in the 
average spectrum from the cancer regions of each biopsy.  Based on these 
criteria, it was determined that there were no statistically significant differences in 
any of the peak intensities between the two biopsies.  It should be noted that 
these are two different needle cores form the same biopsy and thus are not 
identical pieces of tissue. 
The protease hydrolysis step is essential to generate peptide fragments 
derived from non-crosslinked domains and enable identification directly from their 
location in the tissue. Typically, the process generates hundreds of tryptic 
peptides in a mass range (m/z 500-3000) amenable for sequence analysis using 
a MALDI-TOF/TOF instrument.  Thus, selected peptides are desorbed and 
sequenced directly from the tissue and subsequently linked to the respective 
intact proteins originally present.  
Currently, we have identified ~50 proteins directly from the lung tumor 
TMA using MALDI MS/MS sequence analysis (Appendix A). An example of an 
MS/MS spectrum acquired directly from the FFPE-TMA and sequenced as a 
peptide from the protein S100-A9 is shown in Figure 20 (b).  Additionally, five 
fully annotated MS/MS spectra are included in the Appendix B to provide a 
detailed illustration of the spectral quality that can be obtained from carrying out 
MS/MS with a MALDI-TOF/TOF instrument directly from a tissue.  
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The ability to visualize the spatial localization of a set of tryptic peptides 
generated from a single parent protein provides an additional level of validation, 
given that the distribution of these species should be identical. For example, heat 
shock protein beta-1 was found to be localized almost exclusively to the cancer 
regions of a subset of the squamous cell carcinoma biopsies.  Three tryptic 
peptides from this protein were detected and sequenced using MS/MS sequence 
analysis, including m/z 987.60, 1163.62, and 1905.99.  Figure 22(a) shows the 
average spectra for three different squamous cell carcinoma biopsies, including 
two from which the tryptic peptides for heat shock protein beta-1 were was 
detected and identified, and using MS/MS sequence analysis, as well as a third 
biopsy where this protein was not detected.  The zoomed spectra view for the 
three tryptic peptides from this heat shock protein beta-1 show the consistent 
peak distributions for proteins detected at similar levels in different tissue 
samples.  Furthermore, Figure 22(b) illustrates the similar ion density distribution 
of these three peptides across the TMA. 
The layout of the TMA used in these analyses is shown in Figure 23(a). 
This TMA was constructed to contain duplicate needle cores from several of the 
tumor biopsies along with unpaired biopsies and a set of biopsies from adjacent  
non-involved normal lung tissue. For statistical analysis, the duplicate biopsies 
are separated into two datasets; set 1 is used as a training set to build the 
classification models and set 2 is used to evaluate the accuracy of this model 
through cross-validation.  The first step in analyzing the data set generated from 
the imaging experiment is to develop a classification model that can 
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differentiate the different cancer regions from the non-cancer and normal regions. 
The classification models are generated by first grouping together the spectra 
from each of the cancer and non-cancer regions into separate folders for each 
biopsy in the TMA. This is completed using the cancer diagnoses and marked 
histological regions on each biopsy as shown in Figure 23(b).  Since the average 
size of a matrix spot in these analyses is ~175 μm, it is possible that some matrix 
spots are positioned across multiple histological regions, creating a mass 
spectrum partially representative of each of the underlying cell types. In the 
training phase, only spectra that are clearly located within a single histological 
region are included for generating the statistical classification models.  The 
spectra which meet this positional criterion in set 1 of the TMA patient biopsies  
are exported into the appropriate adenocarcinoma, squamous cell carcinoma, 
non-cancer, or normal class groupings to be used for model generation. For 
example, Figure 24 shows the average spectra for a squamous cell carcinoma 
needle core biopsy overlaid with the average spectra from a needle core biopsy 
taken from adjacent normal tissue from same patient.  The peak distributions in 
these two spectra are very different and there are clearly a large number of 
peptides present that can be used as class identifiers.  Several approaches can 
be used to systematically identify peaks that sufficiently distinguish the various 
tumor classes from each other.  The most straightforward way to do this is to 
combine the spectra in each group to create an average spectrum representative 
of a class identified through histology. The peaks present in these average 
spectra can then be compared through statistical analysis to identify a subset of  
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peaks that are significantly different between each group and can therefore be 
used as the class identifiers.  To do this, the statistical software (ClinPro Tools, 
Bruker Daltonics) was used to create a table of average intensity and standard 
deviations for a set of the 200 most intense peaks in the average spectrum for 
both the adenocarcinoma and squamous cell carcinoma samples.  The set of 
200 peaks were evaluated between samples using a t-test and minimum three-
fold intensity difference average comparison to determine a list of class 
identifiers.  The limitation of this method is that it is possible that peaks which 
may be significant among a small subset of spectra in a group will become 
insignificant when averaged with the other spectra in that group.  For example, 
the peptide at m/z 1410.7, a tryptic peptide from keratin, type II cytoskeletal 5 
(KRT5), shows a distribution localized exclusively to a subset of the squamous 
cell carcinoma biopsies (Figure 25).  This is further illustrated when a statistical 
comparison of the average peak intensity in the squamous cell carcinoma 
biopsies for m/z 1410.7 is compared to the set of adenocarcinoma biopsies.  A 
significance analysis using a minimum two-fold intensity difference threshold and 
a t-test shows that when all spectra from each of the adenocarcinoma and 
squamous cell carcinoma biopsies in the training set are combined into two 
average spectra, m/z 1410.7 is not a significant class identifier.  However, when 
a subgroup of squamous cell carcinoma biopsies which do express cytokeratin 5 
are averaged and compared to the adenocarcinoma biopsies, this peak is a 
significant classifier.   
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To address the heterogeneity of peak distributions for biopsies with the 
same diagnosis, it may be necessary to first cluster the samples within each 
histology class based on a similarity criteria.  This is done by comparing the 
average intensity and standard deviation calculated in the average spectrum for 
each individual adenocarcinoma sample in the TMA to the values in the average 
spectrum for each individual squamous cell carcinoma sample and vice versa.   
A similarity value for each comparison was calculated by assessing the number 
of peaks out of the 200 that were determined to be significantly different between 
the two samples.  This value is used to evaluate the heterogeneity of peak 
distributions within a class (i.e. adenocarcinoma) and between classes (i.e. 
adenocarcinoma vs. squamous cell carcinoma).  This similarity value is used as 
a general measure of the reproducibility for this method by comparing the peak 
distributions of two different needle core biopsies that were taken from the same 
patient sample.  A list of class identifiers was developed by tabulating the 
frequency that each peak is determined to be statistically different between the 
individual adenocarcinoma and squamous cell carcinoma samples.  These peaks 
are used to cluster patient samples with the same pathological diagnosis into 
subclasses with other samples having a similar peak distribution. 
It was also possible to classify the adenocarcinoma and squamous cell 
carcinoma regions successfully using the combined average spectra for each 
group to develop a peak list of class identifiers.  The classification models were 
built using a support vector machine (SVM) algorithm which can then classify 
spectra based on the supervised learning from the training set.  The SVM 
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algorithm used in these experiments incorporated 73 peaks, determined through 
statistical comparison of the peaks in the training sets for both adenocarcinoma 
and squamous cell carcinoma as described above.  The SVM model was run 
against all spectra in the data set and the outcome of each classification was 
visualized using the class imaging function in FlexImaging 2.0. For example, 
Figure 26 displays the statistical classification of four TMA biopsies that are in 
agreement with the diagnosis made based on histology.  This model classified 
the spectra from regions marked as adenocarcinoma with an accuracy of 97.9% 
(140/143 spectra) and squamous cell carcinoma with an accuracy of 98.6% 
(141/143 spectra).  Another way to evaluate these data is a comparison of 
individual patients and on this basis, all 19 of the adenocarcinoma biopsies and 
all 24 of the squamous cell carcinoma biopsies were classified correctly.  In the 
adenocarcinoma, the 3 misclassified spectra were dispersed randomly 
throughout the dataset as single occurrences and therefore had little effect on the 
overall patient classifications.  In the squamous cell carcinoma dataset, the two 
misclassified spectra came from a single biopsy in which the remaining 9 out of 
the total 11 spectra were classified correctly as squamous cell carcinoma.  It is 
noted that the MS data was compared to normal histology/pathology, itself not a 
gold standard.   
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Discussion 
A comprehensive understanding of the mechanisms behind 
carcinogenesis, tumor progression, and metastasis will require an in-depth 
analysis of not only the genome, but also the proteome, that direct central 
components in the signaling pathways that drive neoplasia.116 Whereas 
mutations in the genomic contents of cells are known to be the principal cause of 
the onset of carcinogenesis, detecting the changes induced at the protein 
expression level should prove invaluable in characterizing the molecular 
machinery responsible for neoplasia.116 These protein patterns should provide 
information of the underlying cellular processes that control the development of 
cancer and subsequent metastasis. Although mRNA patterns can be used to 
define subclasses and prognostic subsets of lung carcinomas 65, 117-119, they 
generally are not able to identify the proteins expressed in a tissue and how 
these proteins are modulated.  Therefore, direct analysis of the proteome in 
cancer tissues may provide a more accurate representation of the current 
pathological state.   
In this work we provide evidence that using on-tissue digestion coupled 
with imaging mass spectrometry (IMS) and statistical classification distinguishes 
different lung cancer histology’s and sub-classify individual cancer types.  Protein 
expression and relative quantification data can be generated for multiple patient 
tissue samples in a single experiment.  This creates a platform for comparison 
which could be valuable in determining protein markers indicative of various 
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disease states and other clinical information such as prognosis and treatment 
effectiveness.  
The data presented is based on a single TMA for a small patient cohort.  
The experiments described in this work were aimed at demonstrating the 
feasibility of classification of tumor samples in a TMA at the molecular level using 
MALDI IMS.  In order to carry out a more systematic biomarker discovery, it will 
be necessary to evaluate the classification models built using this sample group 
on a much larger set (>100) of patient biopsies.  This will also be essential in 
determining the true diagnostic and prognostic value this method of tissue 
analysis can offer.  In order to effectively manage the enormous dataset 
generated in such experiments, new bioinformatics tools and workflows will need 
to be developed that better allow the user to evaluate model generation and 
classification process. 
One of the primary advantages of IMS is the visualization of the molecular 
content of a sample while maintaining the spatial integrity.  This aspect proves 
essential for the analysis of samples which contain a heterogeneous distribution 
of cell types.  For example, resected lung tumor biopsies exhibit a wide range of 
cellular morphologies, often containing areas of cancer cells dispersed within 
normal and preneoplastic tissue regions.  Analysis of the proteome from these 
various regions requires that the cellular structure of the tissue be maintained.  In 
situ trypsin digestion provides this distinct capability and, when coupled with IMS, 
provides a descriptive analysis of a tissue’s protein contents relatively quickly in a 
single experiment.  Protein identification directly from tissue is not always 
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straightforward because of the large number of peptides generated from 
proteolysis.  We have recently begun analyzing these samples using a Fourier 
transform ion cyclotron resonance mass spectrometer (FT-ICR MS) in an effort to 
address the complexity of the spectra through high resolution and high mass 
accuracy detection.  Although the time-of-flight (TOF) mass analyzer has 
extraordinary analysis speed and throughput, it lacks the mass resolution needed 
to resolve all off the detected ions.  Nonetheless, the advantage of maintaining 
the spatial location of the identified species is critical in achieving a 
comprehensive analysis of these highly heterogeneous tissue samples.    
 
Materials and Methods 
Materials. HPLC grade acetonitrile (ACN) and trifluoroacetic acid (TFA) were 
purchased from Fisher Scientific (Pittsburgh, PA). Alpha-cyano-4-hydroxy-
cinnamic acid (CHCA) was purchased from Fluka (Buchs, Switzerland) and used 
without further purification. Trypsin Gold was purchased from Promega (Madison, 
WI). ITO-coated conductive slides were purchased from Delta-Technologies 
(Stillwater, MN).  Tissue microarray (TMA) consisting of 100 duplicate needle 
core biopsies (1 mm) from 50 patients diagnosed with non-small cell lung cancer 
and 10 adjacent normal lung tissue punches.  The layout of the TMA includes 
duplicate needle core punches from 21 adenocarcinoma biopsies, 21 squamous 
cell carcinoma biopsies, 4 bronchioloalveolar  carcinoma biopsies, 2 metastatic 
colon cancer biopsies, 1 carcinoid biopsy, and 1 plasma cell granuloma biopsy.  
Due to limited numbers for the other cancer types only the adenocarcinoma and 
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squamous cell carcinoma biopsies are considered in these experiments.  Several 
of the needle cores from the adenocarcinoma and squamous cell carcinoma 
biopsies did not contain a sufficient amount of tissue or did not contain regions of 
cancer.  Therefore, the TMA contains a total of 24 squamous cell carcinoma 
needle cores from 15 different patients (7 unpaired, 7 duplicates, and 1 triplicate) 
and 19 adenocarcinoma needle cores from 11 different patients (7 unpaired and 
7 duplicates) that contain cancerous regions and are considered in the study.      
  
Tissue Preparation. Serial 5 µm thick sections were cut from all TMA blocks 
using a microtome. Sections from the TMAs were either mounted onto ITO-
coated conductive slides for MALDI MS analysis 57, or onto regular glass 
microscope slides for H&E staining. Paraffin removal was carried out using 
washes in xylene (100%, twice for 20 min) and graded ethanol washes (100% 
twice for 5 min and in successive washes in 95, 80 and 70% for 5 min each). The 
slides were then allowed to fully dry in an oven for 1 h at 65 °C. Antigen retrieval 
was performed by heating the section in a tris-EDTA buffer at pH 9 at 95°C for 
20 min in a sealed vessel. 
 
On-Tissue Digestion. Trypsin (100 μg) was dissolved in 200 μL of 50 mM acetic 
acid to obtain a stock solution with a concentration of 0.5 μg/μL. A 50 μL aliquot 
of this stock solution was activated by adding 500 μL of 100 mM ammonium 
bicarbonate to reach a pH of ~8 and a final trypsin concentration of 0.045 μg/μL. 
This trypsin solution was automatically spotted onto the TMA tissue sections 
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using a Portrait 630 reagent multi-spotter (Labcyte, Sunnyvale, CA) into an array 
incorporating 250 μm center to center spacing between individual spots, each of 
which were approximately 175 μm in diameter. The trypsin was spotted over a 
series of 30 iterations while depositing 1 drop (~160 pL per drop) each iteration to 
achieve a total spot volume of ~4.8 nL. Between each iteration, the deposited 
trypsin solution was allowed to dry (~5 min time intervals per iteration). The 
trypsin spotting proceeded at room temperature (~21°C) over a time period of 
~2.5 h, allowing ample time for digestion to take place. Following digestion, a 
solution consisting of 10 mg/mL of CHCA in 1:1 ACN/0.5% TFA (aq.) was 
spotted directly onto the array of tryptic spots over 30 iterations at 1 drop per 
iteration.  
 
Imaging Mass Spectrometry of Digested TMA Section. The printed arrays 
were analyzed using an Ultraflex II MALDI TOF/TOF mass spectrometer (Bruker 
Daltonics, Billerica, MA)  equipped with a smart beam laser 97 and controlled by 
the Flex Control 3.0 software package. The mass spectrometer was operated 
with positive polarity in reflectron mode and spectra acquired in the range of m/z 
700-5000. Image acquisition of the spotted arrays was carried out using the Flex 
Imaging 2.0 (Bruker Daltonics, Billerica, MA) software package. A total of 1600 
spectra were acquired at each spot position in a customized spiral raster pattern 
in 200 shot increments at a laser frequency of 200 Hz. The customized raster 
pattern was used to sample the entire spot area. Ion images were assembled 
using the Flex Imaging 2.0 software package.  
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MS/MS Sequence Analysis of Tryptic Peptides.  MALDI MS/MS 
measurements of selected peptides were acquired using TOF/TOF fragmentation 
directly from the digested TMA sections.  Each tryptic peptide sequenced was 
selected and fragmented manually and the generated spectra were processed in 
Flex Analysis 3.0 (Bruker Daltonics, Billerica, MA).  Processing included 25 
cycles of a Savitzky-Golay smoothing algorithm with a width of .15 and baseline 
subtraction using a median algorithm with a flatness value of .5 and a median 
value of .3.  Monoisotopic peaks with a S/N > 8 were selected in each MS/MS 
spectrum using the SNAP peak picking algorithm.  All MS/MS spectra were 
loaded into Biotools 3.0 (Bruker Daltonics, Billerica, MA) and converted into a 
single mascot generic format (.mgf) data file.  This file was submitted into a 
MASCOT (Matrix Science, Boston MA) search engine and run against the Swiss-
Prot database to match tryptic peptide sequences to their respective intact 
proteins. The MS/MS spectrum search was performed with a parent ion tolerance 
of 200 ppm and a fragment ion tolerance of ±0.4 Da. The search criteria also 
included up to 3 missed cleavages and variable modifications including, protein 
N-terminus acetylation, histidine/tryptophan oxidation, and methionine oxidation.  
 
Data Analysis. Statistical analyses of MS profiles were carried out using ClinPro 
Tools 2.0 (Bruker Daltonics, Billerica, MA).  Classes of spectra were loaded into 
the software and baseline correction was achieved using a top hat algorithm with 
a 10% minimal baseline width.  ClinPro Tools automatically normalizes all 
spectra to their own total ion count (TIC). Thus, for each spectrum the TIC is 
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determined as the sum of intensities from all data points in the spectrum. 
Subsequently all data point intensities of this spectrum are divided by the 
obtained TIC value bringing all intensities into the range of [0,1].  Peaks in the 
spectra were selected manually and the maximum intensity within each of the 
defined peak integration areas was used as the comparative value.  The 
classification model used in this analysis was built using a support vector 
machine algorithm (SVM) using 73 peaks determined through statistical 
comparison by means of a t-test and minimum three-fold intensity difference 
average.  The number of neighbors for the K-NN classification parameter in the 
SVM settings was set to 3. 
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CHAPTER IV 
 
 
 
HIGH-THROUGHPUT PROTEOMIC ANALYSIS AND STATISTICAL 
COMPARISON OF MULTIPLE FORMALIN-FIXED PARAFFIN-EMBEDDED 
LUNG CANCER TISSUE MICROARRAYS  
 
 
 
Abstract 
 
 We have previously shown that in situ digestion coupled with imaging 
mass spectrometry can be used to map protein distributions in a large number of 
patient samples compiled into an FFPE-TMA.  However, to elucidate the full 
potential of this technology for the proteomic analysis of FFPE clinical specimens 
it will need to be validated on a sufficiently large sample set.  Here we use this 
method to analyze a set of four TMAs containing samples from 115 different 
NSCLC patients diagnosed with adenocarcinoma and squamous cell carcinoma.  
Statistical analysis of the peptide distributions is conducted to reveal peaks that 
can distinguish the adenocarcinoma patients from the squamous cell carcinoma 
patients with high sensitivity and specificity.  Using these peaks, classification 
models are generated that can accurately identify these NSCLC sub-histologies.  
Several disease relevant proteins were identified directly from histopathological 
regions of interest in these analyses.  Importantly, many of these proteins and 
distributions correlate with results previously reported in the literature.  The data 
presented in this work reveals the potential of this method to aid pathologists in 
differentiating various tissue histologies and elucidating new cancer phenotypes. 
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Introduction 
 
 Pulmonary carcinomas are typically divided into two groups, small cell 
lung cancer (SCLC) and non-small cell lung cancer (NSCLC).  NSCLC is further 
divided into three main histological subtypes: squamous cell carcinoma (SCC), 
adenocarcinoma (AC), and large cell carcinoma (LCC).  The accurate pathologic 
classification of lung cancers to distinguish NSCLC from SCLC is critically 
important as a prognostic factor and in the evaluation of treatment modalities.120  
For example, the biological characteristics and responsiveness to chemotherapy 
is profoundly different for patients with NSCLC (unresponsive) and SCLC 
(responsive).  In many cases, pathologists are able to sufficiently distinguish 
these classes of lung cancer by evaluating the histological features of a biopsy 
with light microscopy.  However, several factors including poorly differentiated 
cells, crush artifact, tumor necrosis, and limited tumor representation can 
preclude making a differential diagnosis using morphological examination 
alone.120   
 In the past, it was generally thought that specific sub-classification of 
NSCLC cases was unnecessary because all subtypes were considered to have 
the same prognosis and were therefore treated in a similar manner.121  However, 
recent advances in targeted molecular based therapies have made the 
recognition and sub-typing of NSCLC increasingly important.  For example, the 
anti-VEGF monoclonal antibody bevacizumab (Avastin; Genentech, South San 
Francisco, CA) is FDA approved for treatment of unresectable, locally advanced, 
recurrent, or metastatic, non-squamous NSCLC.  However, patients with 
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squamous cell carcinoma cannot be administered Avastin because a 30% 
mortality rate has been observed in these individuals due to pulmonary 
hemorrhaging.122, 123   
As with differentiating NSCLC and SCLC, making the distinction in NSCLC 
patients between glandular (AC) and squamous (SCC) differentiation can be 
challenging in poorly differentiated carcinomas, especially in small biopsy tissues 
obtained by bronchoscopy.120  For example, Stang et al. examined the 
agreement in the histopathological evaluation of 688 lung cancer patient tissues 
between two independent pathologists.  The observed agreement was 65% with 
a kappa value of .54 (95% CI: 0.49-0.58).  The kappa statistic is an index which 
compares the agreement against that which might be expected by chance. When 
this value is broken down based on the different histologies examined, it is clear 
that the agreement is highest for the diagnosis of small cell carcinoma (0.94; κ = 
0.82) and significantly lower for squamous cell carcinoma (0.81; κ = 0.55) and 
adenocarcinoma (0.81; κ = 0.55).  Based on these values, the authors concluded 
that “if histological typing of lung cancer beyond the distinction between small-cell 
versus non-small-cell carcinoma is critical in a study, we would suggest to 
generally add ancillary techniques including histochemistry, 
immunohistochemistry, electron microscopy, and other molecular biological 
methods that may increase the reliability of the histopathological evaluation...”  
These limitations have motivated research initiatives which focus on identifying 
molecular markers that could aid pathologists in accurately making a differential 
diagnosis when morphological examination alone is not adequate.   
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 In the previous chapter we demonstrated that in situ digestion followed by 
MALDI IMS analysis could effectively be used to map protein distributions in 
FFPE TMA samples.  In a single experiment, this method was used to 
reproducibly detect hundreds of peptide peaks simultaneously in tissues from 
several different NSCLC patients.  By combining the MS information with the 
histological assessment carried out by the pathologist, the resulting dataset was 
used to determine peak signatures that could sufficiently distinguish the 
adenocarcinoma and squamous cell carcinoma patients.  The potential of this 
technology was clearly established, however further validation of its applicability 
to clinical samples will require analysis of a large number of patient samples 
across multiple TMAs.  Here we apply this method for the proteomic analysis of a 
set of cross institutional TMAs containing a total of 115 different NSCLC patients.  
Peak distributions unique to the different cancer subtypes are identified through 
statistical comparison and used to build classification models.  The biological 
relevance of the proteins detected in these samples is discussed and compared 
to literature reports.        
 
Results 
  In situ tryptic digestion followed by MALDI IMS was conducted on four 
separate FFPE lung cancer TMAs.  A total of 160 separate tissues were 
analyzed in these experiments from 115 NSCLC patients, including 52 diagnosed 
with adenocarcinoma and 63 diagnosed with squamous cell carcinoma.  For 
each TMA section analyzed by mass spectrometry, a serial section was collected 
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and stained with H&E.  The stained sections were reviewed by a pathologist and 
the relevant pathological regions of each tissue were marked accordingly.  These 
annotated images were then overlaid with the sections analyzed using mass 
spectrometry enabling each mass spectrum to be assigned to a specific patient 
and histological region.   
Spectra acquired from regions marked as either adenocarcinoma or 
squamous cell carcinomas were grouped together for statistical analysis.  Each 
spectrum contains several hundred peaks representing a diverse population of 
tryptic peptides.  The monoisotopic peaks present in each spectrum were 
identified and extracted as a peak list containing m/z values and their respective 
intensities.  For statistical analysis, all spectra acquired from each individual 
patient were averaged into a single spectrum and peak distributions in these 
average spectra were then compared. 
  A total of 335 unique monoisotopic peaks were detected in these datasets 
using a S/N 5 cutoff.  It is noted that this value increases to 602 when a S/N of 3 
cutoff is used.  For statistical analysis and classification, it was determined that 
the set of 335 peaks included a sufficient number of classifiers to distinguish the 
two cancer classes and that use of the larger peak lists (602) did not increase the 
accuracy.  However, it is likely that the peak information contained in the 
expanded peak lists generated using a lower S/N threshold does contain 
valuable information and may be especially useful in revealing subtypes within a 
specific histology. 
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Significance analysis of microarrays (SAM) was conducted on the set of 
335 peaks to determine m/z values that were significantly different between the 
two cancers and therefore could be used to distinguish the patient classes.  
Briefly, SAM is a statistical technique originally developed for determining 
significant genes in a set of microarray experiments.124  This method can be 
easily adapted to evaluate protein/peptide expression data in a set of patients 
because the general concept of the two analyses is the same, in that an 
expression level of a specific attribute (gene or protein) is measured.  The input 
to SAM is the peak intensity values across all patients, as well as a class defining 
variable, which in these studies was either squamous cell carcinoma or 
adenocarcinoma.  SAM conducted a two-class unpaired comparison using a t-
statistic over 5000 permutations.  SAM permutes the data by scrambling the label 
of samples and therefore assumes that all null hypotheses are true and there are 
no differences in the peptide expression levels between the two cancer classes.  
For each permutation, SAM assigns a score of relative difference for each peak 
and ranks these by their magnitude.  This value is compared to the expected 
relative difference under the null hypothesis, which is defined as the average of 
the ranked scores of relative difference over all permuted data.  The peaks that 
show relative difference levels deviating from the expected value under the null 
hypothesis by an amount greater than a thresholding parameter, Δ, are 
considered significant.  A minimum fold intensity change value is also used to 
define the significance cutoff value.   
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 The SAM comparison determined a set of 84 peaks out of the set of 335 
that were significantly different between the adenocarcinoma and squamous cell 
carcinoma patients with a minimum 2-fold intensity change and a false discovery 
rate <1 (Figure 27).  In terms of distribution, 58 of these markers were 
significantly higher in the squamous cell carcinoma patients and 26 were higher 
in the adenocarcinoma patients. 
From this set of 84 peaks, a subset of 29 peaks was determined to be 
optimal for distinguishing the two histological classes using a feature selection 
function and was used to build an SVM classification model.  However, through 
careful evaluation of the peaks present across the patients in these datasets it 
became clear that a small percentage of patients diagnosed with 
adenocarcinoma exhibited peak distributions highly consistent with squamous 
cell carcinoma patients and vice versa.  In other words, the spectra from these 
patients’ showed high intensity values for the peaks determined through SAM to 
be significant for the cancer subtype contrary to their diagnosis.  This is clearly 
seen when all patients are clustered based on these 29 peaks, as shown in 
Figure 28.   An even smaller percentage of patients did not express (above 
threshold) any of the 29 peaks used in the model.  In total, 10 patients (3 
adenocarcinoma and 7 squamous cell carcinoma) exhibited peak distributions 
consistent with the opposite class and 6 patients were unclassifiable using these  
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peaks.  Therefore, these outlier patients were excluded from the model 
generation and classification steps. 
Using these 29 peaks, a set of SVM classification models were built that 
could classify the remaining 99 patients with a high degree of accuracy, as 
shown in Table 2.  Models a) and b) are based on an iterative train/test workflow 
where the dataset is split into a training set and a test set.  The SVM model is 
built on a training set using the 29 peaks then used to classify the remaining test 
set.  For model a) the training set consisted of 80% of the patients and the 
remaining 20% were used as the test set.  This splitting process for the training 
and test sets was randomly repeated 100 times and the average classification 
accuracy using this model was 99.3%.  To further demonstrate the robustness of 
these 29 peaks as classifiers, a second SVM model, b), was built using a 50/50 
split for the training and test sets and the average classification accuracy over 
100 repetitions was 98.2%.  Model c) was built using a slightly different 
approach, where the SVM was trained using a set of adenocarcinoma and 
squamous cell carcinoma template spectra.  The template spectra were built 
based on the average value for each peak across all patients from that class.  
The SVM model was then generated using these template spectra and used to 
classify the entire dataset.  This model was able to classify the patients with 
100% accuracy. 
The template model was also used to conduct a spectrum based 
classification, where each individual spectrum from each patient was classified 
without averaging.  The results of this analysis are outlined in d).   
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Discussion 
Here we show that the analysis of FFPE TMAs using on-tissue digestion 
coupled with MALDI IMS can simultaneously reveal the distribution of numerous 
proteins across a large number of patient samples.  One important aspect of this 
technology is that it can be applied to tissues acquired at different institutions, 
and therefore assembled into different TMA blocks, and the results generated 
from these separate analyses can be effectively compared.  We applied this 
methodology to four separate TMAs including two containing NSCLC patient 
samples from Vanderbilt University Medical Center and two assembled by an 
independent biotechnology company (Folio Biosciences; Columbus, OH).     
Several hundred different peptide distributions were detected in these 
samples using IMS.  By combining the MS information with the histological 
evaluation carried out by the pathologist, these distributions can be linked to 
specific cellular regions of interest.  This workflow can discover peak patterns 
that are specific to the squamous cell carcinoma or adenocarcinoma subtypes.  
These peak distributions are then used to develop statistical classification models 
capable of assigning an unknown spectrum from a test set to the appropriate 
class.   
As outlined in Table 2, the models generated were able to classify the 
selected test data with remarkable accuracy using 3 different approaches.  
However, the reported accuracies were contingent upon the removal of a 
relatively small subset of patient outliers from each class.  These patients were 
removed from the dataset prior to conducting the model train/test workflow 
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because they either exhibited peak profiles consistent with the histology contrary 
to that reported during the histological evaluation by the pathologist or they did 
not express any of the peaks used for classification above the threshold levels.   
A number of factors may explain this observation.  For one, the diagnoses 
made by the pathologist, to which the observed peak distributions are compared 
to, are not necessarily a “gold standard”.  As mentioned in the introduction, 
several studies comparing the diagnoses made by independent pathologists on 
NSCLC tissues reported a high level of disagreement.  The subjectivity of using 
morphological examination alone is likely compounded by factors such as poorly 
differentiated cells and limited tissue quantities.  Our method provides an 
objective measurement of protein expression in these patients and therefore 
should not be limited by factors such as a small quantity of tissue or 
undifferentiated cells (provided the underlying biology has not changed).  This 
assertion is backed by the fact that the vast majority of patients in each class 
exhibit a peak profile that can be accurately identified using a panel of 29 peaks.  
However, it is possible that some tumors exhibiting cellular differentiation 
attributed to a specific NSCLC histological subtype, such as adenocarcinoma or 
squamous cell carcinoma, may exhibit proteins that are typically unique to a 
different histology.  This appears to be the case for the patient outliers in our 
dataset seeing that the histological diagnosis assigned to these tissues were 
agreed upon by at least two lung cancer experts. 
These results are very interesting, though not completely unexpected 
when considering the well-known heterogeneity of lung cancer.125  The 
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hierarchical clustering displayed in Figure 28 clearly shows the presence of 
subgroups within the major histological subtypes of squamous cell carcinoma 
and adenocarcinoma.  This elucidates the complexity involved in the 
classification of squamous cell carcinoma and adenocarcinoma subhistologies in 
NSCLC and further highlights the potential of using MS data to go beyond a 
simple two class distinction.  Determining the relevance of these subgroups in 
terms of clinical characteristics will require analysis of a large patient cohort 
where detailed treatment and follow-up information is available.  
The amount of information contained in these NSCLC patient datasets is 
extraordinary.  The combined MS and histological analysis provides an optimal 
platform to compare proteomic distributions between the patients.  For example, 
many of the proteins identified in these analyses are from the cytokeratin family.  
Cytokeratins (CK) are intermediate filament proteins which make up part of the 
integrated cytoskeleton of both normal and malignant epithelial cells.126  
Cytokeratins are grouped into a type I (acidic, CK9 through CK20) and a type II 
(neutral basic, CK1-CK8) gene family.  The individual cytokeratin proteins 
assemble into non-covalent heterodimers containing one type I species and one 
type II species.  These heterodimers are then organized further into filamentous 
structures that in turn provide structural and mechanical stability to cells and their 
respective tissues.126  The expression of cytokeratins in cells is remarkably tissue 
specific and differentiation dependent, suggesting that the pattern of cytokeratin 
species present in cells is related to their biological function.127, 128   
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 Cytokeratin 8 (CK8) and 18 (CK18) are the major components of all 
simple or single layer epithelial tissues.  The carcinomas that arise from these 
tissues typically continue to express CK8 and CK18 and therefore these proteins 
are commonly used as markers of epithelial derived cancers.  Given the 
specialized functions of CK8 and CK18 in the tissues of different organs, such as 
albumin production in liver cells and casein production in mature mammary gland 
cells, it would be expected that their expression would discontinue in parallel to 
other differentiated functions during malignant conversion and progression.129  
However, detection of CK8 and CK18 has commonly been reported in both well 
and poorly differentiated carcinomas.  Oshima et al.129 thoroughly review the 
oncogenic regulation and function of CK8 and CK18 and provide many 
interesting mechanisms behind this continued expression.  In addition to these 
considerations, several reports have shown the presence of CK8/CK18 in tumors 
derived from tissues that do not naturally express these simple epithelial keratins.  
For example, CK8 and CK18 are not found in stratified epithelia.  However, 
squamous cell carcinomas originating from stratified epithelia do show 
anomalous expression of the CK 8/18 pair.129-132   
    In accordance with the aforementioned IHC studies, CK 8 and CK 18 are 
co-expressed in many of the lung tumor biopsies analyzed in these studies, 
including several cases of squamous cell carcinoma.  For example, Figure 29 
shows the corresponding distributions of a CK 8 peptide and a CK 18 peptide in  
3 squamous cell carcinoma biopsies and 1 adenocarcinoma biopsy from a lung 
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Figure 29 a) H&E stained tissues from 3 squamous cell carcinoma (SCC) patients 
and an adenocarcinoma (AC) patient. b) and c) show the co-expression of a peptide 
from CK18 and a peptide from CK8 across the different patient samples. 
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cancer FFPE-TMA.  Currently, we have identified five peptides specific for CK 8 
and four peptides specific for CK 18 in these tissues.  Interestingly, in correlation 
with the IHC studies, three different patterns of CK 8 and CK 18 expression are 
present in this dataset: 1.) CK 8+/CK 18+ 2.) CK 8-/CK 18+ 3.) CK 8+/CK 18-. 
Recently, these proteins have been associated with several important tumor 
characteristics including invasiveness, metastasis, and drug resistance.133  The 
ability of this method to quickly and specifically detect their presence and map 
their distributions in tissues will facilitate future studies of these proteins.  
 In addition to CK8 and CK18, we have identified 12 different cytokeratin 
species in the lung cancer TMAs.  The results of the SAM evaluation clearly 
illustrate the presence of histology dependent cytokeratin distributions with 
distinctly different levels of expression between the two cancer classes.  For 
example, peptides from cytokeratin 5 and 6 (CK5 and CK6) showed highly 
increased expression levels in the squamous cell carcinoma patients.  In terms of 
patients, detectable levels of CK5 were present in 60 (88%) squamous cell 
carcinoma patients and 27 (51%) adenocarcinoma patients and CK6 in 43 (63%) 
squamous cell carcinoma patients and 2 (3%) adenocarcinoma patients. 
These results are interesting when considering the literature reports on the 
distributions of CK5 and CK6.  CK 5/6 is widely used in modern surgical 
pathology because it characteristically stains squamous carcinomas strongly and 
diffusively.  A recent literature report134   argued that a lung tumor that is not CK 
5/6 positive is not squamous cell carcinoma, although this study was carried out 
on a relatively small set of patients (45 NSCLCs: 24 adenocarcinomas and 21 
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squamous cell carcinomas).  Numerous other studies have also shown the ability 
to use a CK 5/6 antibody for distinguishing pulmonary squamous cell carcinomas 
from adenocarcinomas, yet the reported specificity of this marker in 
distinguishing these histologies varies significantly between studies.120, 134-138 
  We conducted a comparison between the peptide distributions from 
these proteins and the IHC distributions using the CK 5/6 antibody.  One 
important aspect of the antibody used in the abovementioned studies and our 
analyses is that it is a mixture of mouse monoclonal antibodies raised against 
purified CK proteins that shows non-specific reactivity against CK5 and CK6.  For 
clarification in the following figure, it should be noted that the TMA used in these 
experiments consists of triplicate needle core biopsies from each patient and 
therefore the layout is such that each row contains 9 tissue cores (3 cores from 3 
different patients).  Interestingly, when the localizations of CK5 and CK6 are 
mapped using peptides unique to each protein it is clear that their distributions 
are not identical.  For example, Figure 30 a.) shows the distribution of the CK 5/6 
antibody using IHC on triplicate biopsies from two patients diagnosed with 
squamous cell carcinoma.  Figures c and b show the distributions of a peptide  
specific for CK5 and CK6, respectively.  These ion density maps show that the 
distributions of CK5 (m/z 1410.7) and CK6 (m/z 1407.7) are not identical, yet due 
to the non-specific binding of the CK5/6 antibody this cannot be readily 
determined using IHC.   
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These results are significant for several reasons.  First, it is important to 
show that the general ion distributions observed in IMS experiments can be 
validated using alternative methods such as IHC.  Furthermore, this scenario 
highlights the superior molecular specificity that can be achieved using mass 
spectrometry as compared to other imaging methods.   
Other ions, such as peptides from the protein cytokeratin 7 (CK7) showed 
intensity fold-change values of up to 15 times higher in the adenocarcinoma 
patients.  Detectable levels of CK7 were present in 49 (95%) of the 
adenocarcinoma patients and 22 (33%) of the squamous cell carcinoma patients.   
CK7 is commonly used in pathology in combination with CK20 to 
discriminate between metastatic and primary tumors from several different 
organs.139  This highlights another potential application of this method: using the 
protein expression patterns detected in a metastatic tumor to determine primary 
sites of origin.  Unfortunately, metastatic cancer with an unknown primary is one 
of the 10 most common cancer diagnoses, with 3-5% of all cancer patients 
presenting with this condition.140  Determining the primary site of tumor origin is 
important for disease management and prognosis in that a more precise cancer 
diagnosis will lead to a more effective course of treatment and ultimately improve 
the overall outcome.   
Adenocarcinomas are the most common malignant neoplasms of 
unknown primary origin, making up about 60% of all cases.140  Determining the 
tissue origin of metastatic adenocarcinoma can be extremely difficult because the 
microscopic appearance of histological features in these neoplasms is not 
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distinctive enough to make a confident diagnosis.  Therefore, a panel of 
molecular markers is needed to assist in evaluating these tumors and identifying 
their tissue of origin.  This method has the ability to quickly detect a phenotype in 
a tissue and therefore could potentially be an extremely powerful way to discern 
the primary sites for malignant tumors.     
 Cytokeratin fragments detected in the sera of cancer patients have shown 
promise to be a simple, cheap, non-invasive and reliable tool for determining 
prognosis and effectiveness of therapy for certain cancers.  The mechanism 
responsible for the release of cytokeratins or cytokeratin fragments into the 
serum is not completely understood, but is thought to involve multiple pathways 
including proteolytic degradation from dying cells, abnormal mitosis, spillover of 
monomeric cytokeratin peptides from proliferating cells, apoptosis, etc.126, 141-143  
Cytokeratin fragments have been detected in a number of body fluids including 
blood, urine, cyst fluids, ascites, pleural effusions, and cerebrospinal fluid 
following release from cancer cells.126  The fact that in normal, apparently healthy 
individuals, the level of cytokeratin fragments detected in circulation is low and 
increases significantly in patients with carcinomas highlights the significance of 
these results. 
Currently, there are three cytokeratin markers which are commonly used 
as prognostic markers in lung cancer: tissue polypeptide antigen (TPA) for CK8, 
18, and19; tissue polypeptide specific antigen (TPS) for CK18; cytokeratin 
fragments 21-1 (Cyfra 21-1) and CK19.  The level of these markers in serum is 
quantified using various commercially available serological assays.  Analysis of 
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the detected levels of these markers in serum has been demonstrated to assist in 
the early detection of recurrence and to enable a rapid assessment of a patient’s 
response to therapy. 
Several studies have reported that these cytokeratins are prognostically 
significant markers in patients with NSCLC.144-146  Most notably, Cyfra 21-1has 
been shown to be an independent predictor of prognosis in NSCLC 147-150, the 
most widely used serum marker for screening and monitoring of lung cancer145, 
149, 151-155, post therapeutic evaluation 153, 156, and indicator of advanced 
disease.155, 157, 158 
Although promising, the current set of serum tumor markers lack the 
reliable specificity and sensitivity necessary to gain wide acceptance as clinical 
tools.  The clinically relevant data that has been collected using a relatively small 
set of tumor markers makes it reasonable to assume that there are additional 
tumor markers present that have yet to be discovered.  As discussed previously 
(Chapter 1), the extreme complexity of blood makes discovery of tumor markers 
difficult.  This limitation has encouraged research focusing on the direct analysis 
of the resected tumor or tumor biopsy to carry out the biomarker discovery 
phase.  It is logical to hypothesize that the concentration of potential biomarkers 
will be highest in the tumor and its adjacent microenvironment.    
 Our work has revealed a complex pattern of cytokeratin expression in 
NSCLC tumors that may account for the inconsistencies in the literature reports 
regarding these tumor markers.  It would be valuable to assess the correlation 
between the levels of these markers in a patient’s serum and the tumor tissue. 
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Most of the previously reported studies looking at NSCLC serum biomarkers 
have been driven under the assumption that these tumors should express similar 
markers during progression.  However, our results indicate that the protein 
expression patterns of these tumors can be markedly different and it is therefore 
likely that a panel of markers will need to be employed to sufficiently detect these 
tumors.   
 In addition to cytokeratins, many other proteins were identified that 
showed histology specific distributions.  Several of these proteins have 
previously been reported to play a role in lung cancer including apolipoprotein A-
I159, carbonyl reductase160, carcinoembryonic antigen161, aldo-keto reductase 
family 1 C1162, alpha enolase162, glutathione s-transferase162, and annexin A2163 
(Figure 31).  These images were all generated simultaneously in a single 
imaging experiment.  This figure helps put into perspective the extraordinary 
amount of information that can be generated in a single FFPE-TMA imaging 
experiment when it is considered that to generate similar information using IHC, 
seven separate experiments would have to be conducted including controls.  
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Figure 31.  Distribution of the peptides identified from 
7 different proteins that have previously been 
associated with NSCLC. 
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Materials and Methods 
Materials. HPLC grade acetonitrile (ACN) and trifluoroacetic acid (TFA) were 
purchased from Fisher Scientific (Pittsburgh, PA). Alpha-cyano-4-hydroxy-
cinnamic acid (CHCA) was purchased from Fluka (Buchs, Switzerland) and used 
without further purification. Trypsin Gold was purchased from Promega (Madison, 
WI). ITO-coated conductive slides were purchased from Delta-Technologies 
(Stillwater, MN).  Four TMAs containing needle core biopsies from NSCLC 
patients were used in these studies.  Two of the TMAs were assembled at 
Vanderbilt University Medical Center and two were assembled by an 
independent biotech company (Folio Biosciences, Columbus OH).  These four 
TMAs consisted of a total of 157 tissues from 115 different patients diagnosed 
with squamous cell carcinoma or adenocarcinoma by a pathologist.  The tissue 
cores in the Folio Biosciences TMAs were 1.5 mm in diameter and the cores in 
the Vanderbilt TMAs were 1 mm in diameter. 
 
Tissue Preparation. Serial 5 µm thick sections were cut from all TMA blocks 
using a microtome. Sections from the TMAs were either mounted onto ITO-
coated conductive slides for MALDI MS analysis 57, or onto regular glass 
microscope slides for H&E staining. Paraffin removal was carried out using 
washes in xylene (100%, twice for 20 min) and graded ethanol washes (100% 
twice for 5 min and in successive washes in 95, 80 and 70% for 5 min each). The 
slides were then allowed to fully dry in an oven for 1 h at 65 °C. Antigen retrieval 
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was performed by heating the section in a tris-EDTA buffer at pH 9 at 95°C for 
20 min. 
 
On-Tissue Digestion. Trypsin (100 μg) was dissolved in 200 μL of 50 mM acetic 
acid to obtain a stock solution with a concentration of 0.5 μg/μL. A 50 μL aliquot 
of this stock solution was activated by adding 500 μL of 100 mM ammonium 
bicarbonate to reach a pH of ~8 and a final trypsin concentration of 0.045 μg/μL. 
This trypsin solution was automatically spotted onto the TMA tissue sections 
using a Portrait 630 reagent multi-spotter (Labcyte, Sunnyvale, CA) into an array 
incorporating 250 μm center to center spacing between individual spots, each of 
which were approximately 175 μm in diameter. The trypsin was spotted over a 
series of 30 iterations while depositing 1 drop (~160 pL per drop) each iteration to 
achieve a total spot volume of ~4.8 nL. Between each iteration, the deposited 
trypsin solution was allowed to dry (~5 min time intervals per iteration). The 
trypsin spotting proceeded at room temperature (~21°C) over a time period of 
~2.5 h, allowing ample time for digestion to take place. Following digestion, a 
solution consisting of 10 mg/mL of CHCA in 1:1 ACN/0.5% TFA (aq.) was 
spotted directly onto the array of tryptic spots over 30 iterations at 1 drop per 
iteration.  
 
Imaging Mass Spectrometry of Digested TMA Section. The printed arrays 
were analyzed using an Ultraflex II MALDI TOF/TOF mass spectrometer (Bruker 
Daltonics, Billerica, MA)  equipped with a smart beam laser 97 and controlled by 
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the Flex Control 3.0 software package. The mass spectrometer was operated 
with positive polarity in reflectron mode and spectra acquired in the range of m/z 
700-5000. Image acquisition of the spotted arrays was carried out using the Flex 
Imaging 2.0 (Bruker Daltonics, Billerica, MA) software package. A total of 1600 
spectra were acquired at each spot position in a customized spiral raster pattern 
in 200 shot increments at a laser frequency of 200 Hz. The customized raster 
pattern was used to sample the entire spot area. Ion images were assembled 
using the Flex Imaging 2.0 software package.  
 
MS/MS Sequence Analysis of Tryptic Peptides.  MALDI MS/MS 
measurements of selected peptides were acquired using TOF/TOF fragmentation 
directly from the digested TMA sections.  Each tryptic peptide sequenced was 
selected and fragmented manually and the generated spectra were processed in 
Flex Analysis 3.0 (Bruker Daltonics, Billerica, MA).  Processing included 25 
cycles of a Savitzky-Golay smoothing algorithm with a width of .15 and baseline 
subtraction using a median algorithm with a flatness value of .5 and a median 
value of .3.  Monoisotopic peaks with a S/N > 8 were selected in each MS/MS 
spectrum using the SNAP peak picking algorithm.  All MS/MS spectra were 
loaded into Biotools 3.0 (Bruker Daltonics, Billerica, MA) and converted into a 
single mascot generic format (.mgf) data file.  This file was submitted into a 
MASCOT (Matrix Science, Boston MA) search engine and run against the Swiss-
Prot database to match tryptic peptide sequences to their respective intact 
proteins. The MS/MS spectrum search was performed with a parent ion tolerance 
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of 200 ppm and a fragment ion tolerance of ±0.4 Da. The search criteria also 
included up to 3 missed cleavages and variable modifications including, protein 
N-terminus acetylation, histidine/tryptophan oxidation, and methionine oxidation.  
 
Spectra Processing.  All spectra were processed using FlexAnalysis 3.0 (Bruker 
Daltonics; Billerica, MA).  Baseline subtraction was carried out using the median 
algorithm with a flatness of .9 and a median level of .5.  The Savitzky-Golay 
smoothing algorithm was used with a width of .2 m/z and 15 cycles.  
Monoisotopic peak picking was performed using the SNAP algorithm with a S/N 
cutoff of 5 and a quality factor threshold of 150.  Within the processing script a 
function was included to perform a statistical internal calibration (mass error ∆ 50 
ppm) and a background peak removal based on a custom list of pre-determined 
peaks (e.g. trypsin autolysis peaks).  
 
Data Processing.  The monoisotopic peak lists were exported from the 
processed spectra using in-house software (Peak List Exporter, Vanderbilt 
MSRC Bioinformatics Core).  These peak lists were then zero-padded (m/z 700-
3000) at a bin interval of .1 Da to create full spectra containing only the 
monoisotopic peaks chosen by the processing software.  Arrayed peak list 
spreadsheets were generated for all patients using ClinPro Tools 2.0 (Bruker 
Daltonics, Billerica, MA).  All spectra from each individual patient were loaded 
into the software as a single class and the peak statistic export function was used 
to generate a spreadsheet containing all peaks and the respective average 
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intensity values of these peaks for each of the 115 patients.  ClinPro Tools 
automatically normalizes all spectra to their own total ion count (TIC). Thus, for 
each spectrum the TIC is determined as the sum of intensities from all data 
points in the spectrum. Subsequently all data point intensities of this spectrum 
are divided by the obtained TIC value bringing all intensities into the range of 
[0,1]. 
 
Statistical Analysis.  Tanagra data mining software164 was used to build and 
evaluate the statistical classification models.  Support vector machine models 
were built using the following parameter settings: Kernel: Normalized Polynomial; 
Polynomial exponent: 3; Gamma for RBF: 0.01; Complexity parameter: 1.00; 
Attribute transformation: Normalization; Kernel for rounding: 1 x 10-12; Tolerance 
for accuracy: .001.  Using the instance selection feature two different types of 
models were built using the train/test function to conduct an iterative training and 
testing workflow.  The models were generated using different proportions to train 
the SVM model (80% and 50%) and the remainder of the dataset was used to 
evaluate the accuracy.  A third model was built using template spectra for the 
adenocarcinoma and squamous cell carcinoma phenotypes.  These spectra 
consisted of the average intensity values for each peak across the respective 
class of patients.  This model was then used to classify all patients in the dataset. 
Hierarchical clustering was carried out using the software program Hierarchical 
Clustering Explorer 3.5 (HCE 3.5).165  The data was clustered without 
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normalization using the complete linkage method and the Pearson correlation 
coefficient similarity/distance measure.    
 
CK 5/6 Immunohistochemistry.  Five micron TMA sections were placed on 
charged slides.  The sections were rehydrated and placed in a heated Target 
Retrieval Solution (Labvision, Fremont, CA). Endogenous peroxidase was 
neutralized with 0.03% hydrogen peroxide followed by a casein-based protein 
block (DakoCytomation, Carpinteria, CA) to minimize nonspecific staining.  The 
sections were incubated with Cytokeratin 5/6 (Catalog ab17133, abcam, 
Cambridge, MA) diluted 1:50 overnight. The Dako Envision+ HRP/DAB System 
(DakoCytomation) was used to produce localized, visible staining.  The slides 
were lightly counterstained with Mayer’s hematoxylin, dehydrated and 
coverslipped. 
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Chapter V 
 
 
 
CONCLUSIONS AND PERSPECTIVES 
 
 
 
A single thin tissue section contains an enormous amount of molecular 
information including proteins, peptides, lipids, and small molecules.  These 
basic entities of biological systems are further arranged into an extensive and 
complex network of spatial arrangements governed by the function and 
physiological state of the underlying cellular components.  IMS has the 
extraordinary ability to effectively detect a wide range of these biomolecules from 
a tissue with minimal sample preparation while maintaining the spatial 
orientation.  However, in its current state, this technology is only capable of 
detecting a subset of species from these classes of molecules.  There are 
several reasons for these limitations ranging from the physical and chemical 
properties of different molecular species (e.g. ionization efficiency, solubility, 
molecular weight...etc.), to the design and detection capability of the mass 
spectrometers used in these analyses.  Therefore, to expand the applicability of 
this technology to a broader assortment of molecules, novel methodologies need 
to be developed.     
One way to enhance the range of detectable species is to implement 
chemical reactions on the tissue prior to the standard sample preparation 
protocols.  Chapter 2 outlines the development of a technique called in situ 
digestion, where an enzyme is used to digest the proteins at precisely defined 
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locations in a tissue prior to MS analysis.  We showed that this process can be 
carried out efficiently and reproducibly using robotic spotters.  The advantages 
and contributions of in situ digestion to this technology are several fold: 1) it 
enables high molecular weight proteins > 30 kDa to be indirectly mapped by 
detecting the distribution of their tryptic peptides; 2) proteins can be identified 
directly from a tissue by MS/MS sequence analysis of the tryptic peptides; 3) It 
enables the analysis of FFPE tissues opening the door to a vast archive of 
clinical samples.   
In summary, the work outlined in Chapter 2 shows the feasibility of 
carrying out on-tissue chemistry prior to an MS analysis to expand the proteomic 
information detected.  Our experiments focused on the use of trypsin; however a 
number of other proteases were successfully tested and could potentially be 
used to target different subsets of analytes.  Furthermore, we were able to use a 
combination of enzymes, PNGase F and trypsin, to cleave and identify the 
carbohydrate constituent of the glycoprotein Copeptin.  These results highlight 
the enormous potential that exists to further develop novel tissue chemical 
treatment methodologies prior to IMS analysis. 
Experiments involving FFPE tissues are complicated by the very nature of 
the fixation process itself, in that the chemical modifications that preserve these 
samples render them unsuitable for routine proteomic analysis.  The 
development of antigen retrieval techniques over the past decade was a vital 
step in making these samples accessible to different molecular analysis 
techniques including mass spectrometry.  However, in terms of IMS experiments 
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where a tissue section is kept intact, it is highly unlikely that antigen retrieval 
completely de-crosslinks the proteins.  This makes protein extraction directly 
from the surface of a tissue difficult and helps explain the fact that protein 
imaging experiments conducted on antigen retrieved FFPE sections have 
generally produced low quality data.  Interestingly, we show in Chapter 3 and 4 
that in situ digestion coupled with IMS has the ability to generate high quality 
tryptic peptide profiles comparable to those observed using fresh frozen tissues.  
Without antigen retrieval, in situ digestion is not possible, in that no tryptic 
peptides are observed in the MS analysis.  This seems to indicate that the 
antigen retrieval step serves to provide a partial protein de-crosslinking as well as 
a denaturing effect that enables the enzyme access to carry out digestion.  
Further systematic studies are needed to elucidate the details of this mechanism 
but our results show that these analyses can be carried out reproducibly and 
provide meaningful data. 
One distinct advantage of working with FFPE specimens is the ability to 
compile numerous patient tissues into a single TMA.  A TMA takes a relatively 
small representative region from each individual patient and enables a high-
throughput comparison to be performed.  This provides an unparalleled platform 
for examining different protein distributions between patients in a large sample 
cohort.  Working with a TMA, as opposed to each patient sample individually, 
avoids the effects of day-to-day fluctuations in the sample preparation and mass 
spectrometric analysis steps.  It can be assumed that each sample in the TMA 
underwent nearly identical preparation (e.g. trypsin/ matrix application) and that 
 117 
 
the working order of the mass spectrometer was constant during the analysis.  
Analysis of a large number of individual patient samples may take several days 
or even weeks to complete.  This is an important consideration due to the 
sensitivity of the mass spectrometer, where even slight fluctuations in sample 
preparation or instrument status can create bias in the acquired data.   
  However, there are cases, including analysis of highly heterogeneous 
samples, where it may be necessary to acquire data from the entire patient tissue 
to accurately assess the molecular profile.  In general though, the typical 500-
1500 μm core taken for a TMA should provide a sufficient representation of the 
bulk sample, and usually duplicate cores are taken from each sample in order to 
evaluate the consistency.   
In summary, we have shown the potential of using in situ digestion 
coupled with IMS for the high-throughput proteomic analysis of TMAs.  The 
relative intensity and distribution of hundreds of proteins can be simultaneously 
mapped in a single experiment.  We showed that these experiments are 
reproducible within and between TMAs and therefore the results from multiple 
analyses can be effectively compared.  This platform provides a degree of speed 
and depth that cannot be achieved using any alternative technique, and therefore 
has the potential to revolutionize the molecular analysis of clinical samples. 
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Appendix A 
Protein Identification 
Search Parameters 
Type of search: MS/MS Ion Search 
Enzyme: Trypsin 
Variable modifications: N-Acetyl, Ox. (M/H/W) 
Mass values: Monoisotopic 
Protein Mass: Unrestricted 
Peptide Mass Tolerance : ± 200 ppm 
Fragment Mass Tolerance: ± 0.4 Da 
Max Missed Cleavages: 3 
Instrument type: MALDI-TOF-TOF 
Number of queries: 123 
SwissProt Decoy False discovery rate 
Matches above identity threshold 94 0 0 
Matches above homology or identity threshold 102 1 0.98 
Keratin, type II cytoskeletal 6A  Score (233) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1016.5420 1015.5347 1015.5298 4.83 0 41 0.0094 R.QLDSIVGER.G 
1165.5830 1164.5757 1164.5775 -1.51 0 62 5.7e-05 K.YEELQVTAGR.H 
1263.6915 1262.6842 1262.687 -2.22 0 81 9.2e-07 K.LALDVEIATYR.K 
1407.7100 1406.7027 1406.7041 -1.01 0 34 0.044 K.ADTLTDEINFLR.A 
1890.9550 1889.9477 1889.9635 -8.36 0 92 7.1e-08 R.QNLEPLFEQYINNLR.R 
2047.0294 2046.0221 2046.0646 -20.77 1 21 0.88 R.QNLEPLFEQYINNLRR.Q 
2471.1831 2470.1758 2470.1798 -1.61 3 82 7.1e-07 R.GMQDLVEDFKNKYEDEINKR.T 
Keratin, type II cytoskeletal 5  Score (198) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1016.5420 1015.5347 1015.5298 4.83 0 41 0.0094 R.QLDSIVGER.G 
1093.5220 1092.5147 1092.5199 -4.78 0 21 0.67 K.AQYEEIANR.S 
1263.6915 1262.6842 1262.687 -2.22 0 81 9.2e-07 K.LALDVEIATYR.K 
1410.7325 1409.7252 1409.7151 7.21 0 44 0.0042 R.SFSTASAITPSVSR.T 
1439.7126 1438.7053 1438.7053 0.04 0 66 2.6e-05 R.GLGVGFGSGGGSSSSVK.F 
1890.9550 1889.9477 1889.9635 -8.36 0 92 7.1e-08 R.QNLEPLFEQYINNLR.R 
2047.0294 2046.0221 2046.0646 -20.77 1 21 0.88 R.QNLEPLFEQYINNLRR.Q 
Keratin, type II cytoskeletal 8  Score (144) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1129.6152 1128.6079 1128.6138 -5.25 0 48 0.0019 K.LSELEAALQR.A 
1277.6904 1276.6831 1276.7027 -15.31 0 22 0.7 K.LALDIEIATYR.K 
1419.7931 1418.7858 1418.7405 31.9 0 64 4.7e-05 R.LEGLTDEINFLR.Q 
1847.8475 1846.8402 1846.7978 23.0 0 83 5.8e-07 R.SNMDNMFESYINNLR.R 
1863.8770 1862.8697 1862.7927 41.4 0 (49) 0.0013 R.SNMDNMFESYINNLR.R + Oxidation (M) 
Histone H2A  Score (146) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
944.5400 943.5327 943.524 9.27 0 17 2.1 R.AGLQFPVGR.V 
2915.5000 2914.4927 2914.5804 -30.07 0 146 2.8e-13 R.VGAGAPVYLAAVLEYLTAEILELAGNAAR.D 
Alpha-enolase  Score (122) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1129.6152 1128.6079 1128.6138 -5.25 0 48 0.0019 K.LSELEAALQR.A 
1277.6904 1276.6831 1276.7027 -15.31 0 22 0.7 K.LALDIEIATYR.K 
1419.7931 1418.7858 1418.7405 31.9 0 64 4.7e-05 R.LEGLTDEINFLR.Q 
1847.8475 1846.8402 1846.7978 23.0 0 83 5.8e-07 R.SNMDNMFESYINNLR.R 
1863.8770 1862.8697 1862.7927 41.4 0 (49) 0.0013 R.SNMDNMFESYINNLR.R + Oxidation (M) 
Keratin, type I cytoskeletal 19  Score (105) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1082.5175 1081.5102 1081.4829 25.3 0 27 0.16 K.DAEAWFTSR.T 
1122.5560 1121.5487 1121.5717 -20.45 0 40 0.01 R.LEQEIATYR.S 
1210.6031 1209.5958 1209.5778 14.9 1 32 0.06 R.KDAEAWFTSR.T 
1222.6390 1221.6317 1221.6353 -2.95 1 55 0.00033 R.TKFETEQALR.M 
1354.6100 1353.6027 1353.5983 3.28 0 37 0.018 R.SQYEVMAEQNR.K 
1554.7480 1553.7407 1553.7434 -1.74 0 42 0.0065 R.QSSATSSFGGLGGGSVR.F 
1674.8083 1673.8010 1673.7685 19.4 0 50 0.001 R.DYSHYYTTIQDLR.D 
2407.2258 2406.2185 2406.3019 -34.66 0 30 0.12 R.FGAQLAHIQALISGIEAQLGDVR.A 
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Tubulin beta-2C chain  Score (118) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1130.6021 1129.5948 1129.588 6.04 0 64 4.2e-05 R.FPGQLNADLR.K 
1143.6100 1142.6027 1142.627 -21.27 0 29 0.15 K.LAVNMVPFPR.L 
1601.8101 1600.8028 1600.8131 -6.40 0 75 3.8e-06 R.AVLVDLEPGTMDSVR.S 
1620.8260 1619.8187 1619.8283 -5.89 0 31 0.086 R.LHFFMPGFAPLTSR.G 
2798.4248 2797.4175 2797.3361 29.1 0 37 0.023 R.SGPFGQIFRPDNFVFGQSGAGNNWAK.G 
Serum albumin precursor  Score (113) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
927.4923 926.4850 926.4861 -1.18 0 24 0.34 K.YLYEIAR.R 
1467.8109 1466.8036 1466.8358 -21.92 1 33 0.051 R.RHPDYSVVLLLR.L 
1511.7955 1510.7882 1510.8355 -31.31 0 55 0.00038 K.VPQVSTPTLVEVSR.N 
1623.7710 1622.7637 1622.7803 -10.21 0 59 0.00014 K.DVFLGMFLYEYAR.R 
1639.7600 1638.7527 1638.7752 -13.72 0 (47) 0.0021 K.DVFLGMFLYEYAR.R + Oxidation (M) 
1898.9000 1897.8927 1897.9879 -50.15 1 30 0.11 R.RHPYFYAPELLFFAK.R 
Keratin, type II cytoskeletal 75  Score (110) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1165.5830 1164.5757 1164.5775 -1.51 0 62 5.7e-05 K.YEELQVTAGR.H 
1263.6915 1262.6842 1262.6870 -2.22 0 81 9.2e-07 K.LALDVEIATYR.K 
Keratin, type II cytoskeletal 2 epidermal  Score (103) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1263.6915 1262.6842 1262.687 -2.22 0 81 9.2e-07 K.LALDVEIATYR.K 
1320.6698 1319.6625 1319.5756 65.9 0 53 0.00057 R.HGGGGGGFGGGGFGSR.S 
1475.7600 1474.7527 1474.778 -17.13 0 21 0.83 R.FLEQQNQVLQTK.W 
Keratin, type I cytoskeletal 16  Score (94) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1036.5272 1035.5199 1035.525 -4.90 1 29 0.11 K.IRDWYQR.Q 
1122.5560 1121.5487 1121.5717 -20.45 0 40 0.01 R.LEQEIATYR.R 
1241.5970 1240.5897 1240.587 2.22 0 35 0.031 K.NHEEEMLALR.G 
1259.6740 1258.6667 1258.6669 -0.18 1 41 0.0082 R.TKYEHELALR.Q 
1757.8680 1756.8607 1756.8784 -10.06 1 34 0.045 R.QRPSEIKDYSPYFK.T 
2064.1130 2063.1057 2063.1375 -15.38 0 67 2.4e-05 K.IIAATIENAQPILQIDNAR.L 
Vimentin  Score (88) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1428.7123 1427.7050 1427.7045 0.38 0 77 2.4e-06 R.SLYASSPGGVYATR.S 
2497.2173 2496.2100 2496.2496 -15.86 1 41 0.0089 R.LLQDSVDFSLADAINTEFKNTR.T 
Keratin, type I cytoskeletal 15  Score (108) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1122.5560 1121.5487 1121.5717 -20.45 0 40 0.01 R.LEQEIATYR.S 
1248.6610 1247.6537 1247.6873 -26.94 1 45 0.0037 R.LKYENELALR.Q 
1821.8787 1820.8714 1820.8766 -2.84 0 77 2.4e-06 R.GGSLLAGGGGFGGGSLSGGGGSR.S 
1877.8959 1876.8886 1876.8803 4.42 0 41 0.0079 M.TTTFLQTSSSTFGGGSTR.G + Acetyl (N-term) 
Ferritin light chain  Score (101) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1607.7820 1606.7747 1606.7991 -15.17 0 84 4.5e-07 R.LGGPEAGLGEYLFER.L 
1719.9220 1718.9147 1718.9791 -37.46 1 49 0.0014 K.KLNQALLDLHALGSAR.T 
Protein S100-A9  Score (72) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1455.7142 1454.7069 1454.7154 -5.82 0 18 1.6 K.LGHPDTLNQGEFK.E 
1614.7900 1613.7827 1613.7945 -7.32 0 53 0.00062 K.QLSFEEFIMLMAR.L 
1806.9113 1805.9040 1805.9312 -15.04 0 51 0.00087 R.NIETIINTFHQYSVK.L 
Keratin, type I cytoskeletal 13  Score (71) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1122.5560 1121.5487 1121.5717 -20.45 0 40 0.01 R.LEQEIATYR.S 
1248.6610 1247.6537 1247.6873 -26.94 1 45 0.0037 R.LKYENELALR.Q 
1392.6880 1391.6807 1391.6867 -4.32 0 51 0.00082 K.MIGFPSSAGSVSPR.S 
78 kDa glucose-regulated protein precursor  Score (78) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1566.7791 1565.7718 1565.7726 -0.48 0 51 0.00078 R.ITPSYVAFTPEGER.L 
1999.0770 1998.0697 1998.0786 -4.44 0 58 0.0002 R.GVPQIEVTFEIDVNGILR. 
Keratin, type I cytoskeletal 17  Score (62) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1036.5272 1035.5199 1035.5250 -4.90 1 29 0.11 K.IRDWYQR.Q 
1122.5560 1121.5487 1121.5717 -20.45 0 40 0.01 R.LEQEIATYR.R 
1222.6390 1221.6317 1221.6353 -2.95 1 55 0.00033 R.TKFETEQALR.L 
2114.0249 2113.0176 2113.011 3.14 0 26 0.32 R.GQVGGEINVEMDAAPGVDLSR.I 
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Pulmonary surfactant-associated protein A1 precursor  Score (103) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1447.7350 1446.7277 1446.699 19.8 0 52 0.00069 R.NPEENEAIASFVK.K 
1506.8000 1505.7927 1505.7759 11.1 0 23 0.51 R.GALSLQGSIMTVGEK.V + Ox.(M) 
1984.0176 1983.0103 1983.0425 -16.22 1 37 0.023 R.IAVPRNPEENEAIASFVK.K 
2106.9856 2105.9783 2105.9694 4.22 0 48 0.002 K.YNTYAYVGLTEGPSPGDFR.Y 
2329.1340 2328.1267 2328.1499 -9.94 0 61 8.4e-05 R.GPPGLPAHLDEELQATLHDFR.H + Ox. (HW) 
Tubulin beta-2A chain  Score (74) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1130.6021 1129.5948 1129.588 6.04 0 64 4.2e-05 R.FPGQLNADLR.K 
1143.6100 1142.6027 1142.627 -21.27 0 29 0.15 K.LAVNMVPFPR.L 
1615.8186 1614.8113 1614.8287 -10.76 0 20 1.1 R.AILVDLEPGTMDSVR.S 
1620.8260 1619.8187 1619.8283 -5.89 0 31 0.086 R.LHFFMPGFAPLTSR.G 
2798.4248 2797.4175 2797.3361 29.1 0 37 0.023 R.SGPFGQIFRPDNFVFGQSGAGNNWAK.G 
Histone H4  Score (57) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
989.5700 988.5627 988.5706 -7.91 0 36 0.025 K.VFLENVIR.D 
1325.7233 1324.7160 1324.7463 -22.84 0 54 0.00044 R.DNIQGITKPAIR.R 
Keratin, type I cytoskeletal 18  Score (82) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
965.4800 964.4727 964.4614 11.7 0 36 0.024 R.AQYDELAR.K 
975.4492 974.4419 974.4458 -3.91 0 31 0.085 R.STFSTNYR.S 
2670.3108 2669.3035 2669.3846 -30.38 0 48 0.0018 R.YALQMEQLNGILLHLESELAQTR.A 
2854.3882 2853.3809 2853.4005 -6.88 0 50 0.0012 R.SLGSVQAPSYGARPVSSAASVYAGAGGSGSR.I 
Actin, cytoplasmic  Score (90) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
976.4540 975.4467 975.441 5.84 0 30 0.1 K.AGFAGDDAPR.A 
1515.6600 1514.6527 1514.7419 -58.85 0 59 0.00014 K.IWHHTFYNELR.V 
1790.8907 1789.8834 1789.8846 -0.67 0 61 8.9e-05 K.SYELPDGQVITIGNER.F 
2215.0000 2213.9927 2214.0627 -31.60 0 28 0.19 K.DLYANTVLSGGTTMYPGIADR.M 
Vitronectin precursor  Score (56) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1314.6980 1313.6907 1313.6728 13.6 1 29 0.14 R.RVDTVDPPYPR.S 
1646.8475 1645.8402 1645.81 18.3 0 54 0.00042 R.DVWGIEGPIDAAFTR.I 
1666.7800 1665.7727 1665.7682 2.72 0 30 0.11 R.DWHGVPGQVDAAMAGR.I 
Glutathione S-transferase P  Score (46) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1337.7000 1336.6927 1336.718 -18.89 0 29 0.13 M.PPYTVVYFPVR.G 
1883.9390 1882.9317 1882.9425 -5.72 0 46 0.0031 K.FQDGDLTLYQSNTILR.H 
Keratin, type II cytoskeletal 7  Score (61) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1277.6904 1276.6831 1276.7027 -15.31 0 22 0.7 K.LALDIEIATYR.K 
1406.7100 1405.7027 1405.699 2.63 0 61 7.9e-05 M.SIHFSSPVFTSR.S + Acetyl (N-term) 
1442.7550 1441.7477 1441.7929 -31.33 0 21 0.89 R.LPDIFEAQIAGLR.G 
1453.8199 1452.8126 1452.83 -11.96 0 28 0.16 R.EVTINQSLLAPLR.L 
Ig alpha chain C region  Score (63) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1213.6259 1212.6186 1212.6251 -5.35 0 32 0.064 R.WLQGSQELPR.E 
1835.9080 1834.9007 1834.9425 -22.77 0 63 5.4e-05 R.QEPSQGTTTFAVTSILR.V 
Pyruvate kinase isozymes M1/M2  Score (68) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1859.8700 1858.8627 1858.8924 -15.96 0 46 0.0026 K.FGVEQDVDMVFASFIR.K 
2465.2520 2464.2447 2464.2849 -16.32 0 55 0.00036 R.TATESFASDPILYRPVAVALDTK.G 
Fibrinogen beta chain precursor  Score (50) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
980.4486 979.4413 979.4359 5.50 0 39 0.011 R.QDGSVDFGR.K 
1239.5300 1238.5227 1238.5105 9.88 0 25 0.26 K.EDGGGWWYNR.C 
1950.9750 1949.9677 1949.9959 -14.45 0 39 0.015 R.EEAPSLRPAPPPISGGGYR.A 
Fibrinogen gamma chain precursor  Score (47) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1117.5070 1116.4997 1116.52 -18.14 0 38 0.019 R.VELEDWNGR.T 
1682.9268 1681.9195 1681.9515 -19.02 0 40 0.0099 K.IHLISTQSAIPYALR.V 
Heat shock protein beta-1 Score (50) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
987.5430 986.5358 986.6025 -67.68 1 42 0.0069 R.RVPFSLLR.G 
1163.6035 1162.5962 1162.6135 -14.86 0 20 0.94 R.LFDQAFGLPR.L 
1905.9900 1904.9827 1904.9843 -0.85 0 41 0.0095 K.LATQSNEITIPVTFESR.A 
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Proteins Identified with De Novo Sequencing 
 
Collagen alpha-1(I) chain precursor 
Observed Mr(expt) Mr(calc) ppm Miss Peptide 
1105.578 1104.570 1104.567 2.8 0 GVQGPPGPAGPR (Hydroxylated) 
1459.711 1458.703 1458.759 38.4 0 GSAGPPGATGFPGAAGR (Hydroxylated) 
898.484 897.476 897.502 29.5 0 GVVGLPGQR (Hydroxylated) 
2705.260 2704.252 2704.247 1.9 0 GFSGLQGPPGPPGSPGEQGPSGASGPAGPR (Hydroxylated) 
2869.418 2868.410 2868.399 3.7 1 GLTGPIGPPGPAGAPGDKGESGPSGPAGPTGAR (Hydroxylated) 
Collagen alpha-2(I) chain precursor 
Observed Mr(expt) Mr(calc) ppm Miss Peptide 
1477.760 1476.752 1476.747 3.7 0 GLHGEFGLPGPAGPR (Hydroxylated) 
1562.804 1561.796 1561.781 9.9 0 GETGPSGPVGPAGAVGPR 
1493.771 1492.763 1492.742 14.4 0 GLHGEFGLPGPAGPR (Hydroxylated) 
1533.719 1532.711 1532.667 28.7 0 GDGGPPGMTGFPGAAGR (Hydroxylated) 
1655.823 1654.815 1654.806 5.7 1 GFPGADGVAGPKGPAGER  (Hydroxylated) 
2959.415 2958.407 2958.348 19.8 0 GPPGAAGAPGPQGFQGPAGEPGEPGQTGPAGAR (Hydroxylated) 
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Tentative Protein Identifications (<2 Peptides) 
 
Protein disulfide-isomerase precursor  Score (50) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1780.8400 1779.8327 1779.8275 2.93 0 50 0.001 K.VDATEESDLAQQYGVR.G 
Fibrinogen alpha chain precursor  Score (78) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1520.7173 1519.7100 1519.7267 -10.96 0 78 1.7e-06 K.GLIDEVNQDFTNR.I 
Aldo-keto reductase family 1 member C1  Score (85) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
2179.0750 2178.0677 2178.0817 -6.44 0 85 3.8e-07 R.HIDSAHLYNNEEQVGLAIR.S 
Glyceraldehyde-3-phosphate dehydrogenase  Score (79) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1763.8364 1762.8291 1762.7951 19.3 0 79 1.5e-06 K.LISWYDNEFGYSNR.V 
Carbonyl reductase [NADPH] 1  Score (72) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1652.8300 1651.8227 1651.8642 -25.09 0 72 8e-06 R.GQAAVQQLQAEGLSPR.F 
Hemoglobin subunit alpha  Score (69) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1833.9000 1832.8927 1832.8846 4.43 0 69 1.6e-05 K.TYFPHFDLSHGSAQVK.G 
Annexin A1  Score (63) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1702.8875 1701.8802 1701.8785 1.03 0 63 6e-05 K.GLGTDEDTLIEILASR.T 
Carcinoembryonic antigen-related cell adhesion molecule 5  Score (69) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
2177.0930 2176.0857 2176.1277 -19.28 0 69 1.4e-05 R.QIIGYVIGTQQATPGPAYSGR.E 
Apolipoprotein A-I precursor  Score (53) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1301.6510 1300.6437 1300.6411 1.98 0 53 0.00059 R.THLAPYSDELR.Q 
Histone H2B  Score (47) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1759.8075 1758.8002 1758.8069 -3.80 0 47 0.0015 K.AMGIMNSFVNDIFER.I + Ox. (M) 
Annexin A2  Score (47) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1111.5660 1110.5587 1110.5458 11.6 0 47 0.0019 R.QDIAFAYQR.R 
Macrophage migration inhibitory factor  Score (50) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1287.6816 1286.6743 1286.6805 -4.82 0 50 0.001 M.PMFIVNTNVPR.A 
Serum amyloid P-component precursor  Score (45) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1156.5970 1155.5897 1155.5924 -2.32 0 45 0.0034 R.VGEYSLYIGR.H 
Tubulin alpha-1A chain  Score (45) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1701.8616 1700.8543 1700.8985 -25.98 0 45 0.0037 R.AVFVDLEPTVIDEVR.T 
Stathmin  Score (49) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1388.7150 1387.7077 1387.7459 -27.54 0 49 0.0012 R.ASGQAFELILSPR.S 
Peptidyl-prolyl cis-trans isomerase A  Score (46) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1987.9899 1986.9826 1987.0051 -11.32 0 46 0.0029 M.VNPTVFFDIAVDGEPLGR.V + Acetyl (N-term) 
Protein disulfide-isomerase A3 precursor  Score (46) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1370.7358 1369.7285 1369.6878 29.8 0 46 0.0024 R.ELSDFISYLQR.E 
Histone H3-like  Score (45) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
788.4709 787.4636 787.4704 -8.67 1 45 0.0035 R.KLPFQR.L 
Polymeric immunoglobulin receptor precursor  Score (48) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1228.7552 1227.7479 1227.7551 -5.82 0 48 0.0019 R.LVSLTLNLVTR.A 
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Heterogeneous nuclear ribonucleoproteins A2/B1  Score (46) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1377.6200 1376.6127 1376.6222 -6.88 0 46 0.0024 R.GGGGNFGPGPGSNFR.G 
Protein S100-P  Score (47) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1854.8900 1853.8827 1853.8903 -4.09 0 47 0.0023 M.TELETAMGMIIDVFSR.Y + Acetyl (N-term) 
Myosin-9 - Homo sapiens (Human)  Score (43) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1869.9500 1868.9427 1868.9592 -8.80 0 43 0.005 K.ANLQIDQINTDLNLER.S 
Keratin, type II cytoskeletal 3  Score (81) 
Observed Mr(expt) Mr(calc) ppm Miss Score Expect Peptide 
1263.6915 1262.6842 1262.6870 -2.22 0 81 9.2e-07 K.LALDVEIATYR.K 
Hemoglobin subunit beta  Score (66) 
1274.7000 1273.6927 1273.7183 -20.07 0 66 2.9e-05 R.LLVVYPWTQR.F 
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Fully Annotated MS/MS Spectra 
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